

**Federico Innocenti, MD, PhD**

**CURRICULUM VITAE**

*This curriculum vitae is the result of the collective contribution of several individuals*

**PERSONAL**

**Place of birth:** Pisa (Italy)

**Citizenship:** Italian

**Residence:** Permanent resident in the United States of America (green card valid until 2027)

**Mailing address:**

University of North Carolina, Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics

1014 Genetic Medicine Bldg  
CB 7361, 120 Mason Farm Rd.  
Chapel Hill, NC 27599-7361  
Tel: 919-966-9422  
Fax: 919-966-5863  
[innocent@unc.edu](mailto:innocent@unc.edu)

**EDUCATION**

Residency/Post-graduate School of Oncology, *magna cum laude*, University of Pisa, Pisa, Italy (2002 - 2006)

Ph.D. in Pharmacology, Toxicology, and Chemotherapy [dissertation title: Pharmacogenomic studies on UDP-glucuronosyltransferases (UGTs) in cancer chemotherapy]. University of Pisa, Pisa, Italy (1999 - 2002)

Residency/Post-graduate School of Pharmacology, *magna cum laude*, University of Pisa, Pisa, Italy (1994 - 1998)

M.D., *magna cum laude*, School of Medicine, University of Pisa, Pisa, Italy (dissertation title: Experimental pharmacokinetics and cytotoxicity of paclitaxel) (1986 - 1993)

**PROFESSIONAL EXPERIENCE**

**Main Faculty Appointments**

Associate Professor with Permanent Tenure, University of North Carolina at Chapel Hill, Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, Chapel Hill, NC (December 2014 - present)

Associate Director, Center for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, NC (2013 - 2019)

Associate Professor, University of North Carolina at Chapel Hill, Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, Chapel Hill, NC (2011 - 2014)

Associate Director for Oncology Research, Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, NC (2011- 2013)

Assistant Professor, University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL (2004 - 2010)

Research Associate (Assistant Professor), University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL (2002 - 2004)

Research Associate (Instructor), University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL (2001 - 2002)

### **Additional Appointments**

Member, UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC (2011 - present)

Research Associate Professor, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC (2011 - present)

Member, Carolina Center for Genome Sciences, University of North Carolina at Chapel Hill, Chapel Hill, NC (2011 - present)

Member, Center for Personalized Therapeutics, University of Chicago, Chicago, IL (2010)

Member, Cancer Research Center, University of Chicago, Chicago, IL (2005 - 2010)

Member, Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, IL (2004 - 2010)

Affiliate Member, Cancer Research Center, University of Chicago, Chicago, IL (2001 - 2005)

Associate Member, Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, IL (2001 - 2004)

Research Associate, University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL (1999 - 2001)

Visiting Post-doctoral Fellow, Committee on Clinical Pharmacology, University of Chicago, Chicago, IL (1998 - 1999)

Research Assistant, University of Pisa, Pisa, Italy (1993 - 1998)

### **Licensure**

Medical License to practice as a medical doctor in the countries of the European Union, University of Pisa, Pisa, Italy (1993 - present)

### **National Scientific Qualifications**

Full Professor of Hematology, Oncology, and Rheumatology - Italy (10/31/2018 - 10/31/2024)

Full Professor of Pharmacology, Clinical Pharmacology, and Pharmacognosy - Italy (2/6/2014 - 2/6/2020)

### **Leadership and Activity in Professional Organizations**

#### NIH National Cancer Institute (NCI)

Member - National Clinical Trial Network, Core Correlative Sciences Committee-B (2018 - present)

Ad hoc reviewer - National Clinical Trials Network, Core Correlative Sciences Committee (2015 - present)

Translational Science Representative - Gastrointestinal Steering Committee - Colon Task Force - (2013 - 2019)

Member - Genomics Sub-Committee - Gastrointestinal Steering Committee - ASSIGN Clinical Trial (2014 - 2015)

Member - Investigational Drug Steering Committee - Pharmacology Task Force (2006 - 2011)

#### Alliance for Clinical Trials in Oncology

Co-Chair - Foundation Scholar Award review committee (2015)

Cadre Member - Pharmacogenomics and Population Pharmacology Committee (2012 - present)

Chair - Gastrointestinal Solid Tumor Correlative Science Group (2011 - present)

Vice-Chair - Gastrointestinal Solid Tumor Committee (2011 - present)

Member - Cancer and Leukemia Group B (CALGB) Foundation Review Committee: Clinical Scholar and Young Investigator Awards (2011 - 2012)

Cadre Member - Pharmacology and Experimental Therapeutics Committee (2001 - 2011)

#### American Society of Clinical Oncology (ASCO)

Member - Conquer Cancer Foundation of ASCO Grants Selection Committee (2011 - 2013)

Member - Scientific Program Committee, Developmental Therapeutics - Clinical Pharmacology and Immunotherapy Track (2009 - 2011)

Member - Scientific Program Committee, Developmental Therapeutics - Cytotoxic Chemotherapy Track (2008 - 2009)

#### American Society of Clinical Pharmacology and Therapeutics (ASCPT)

Chair - Oncology Section (2012 - 2013)

Member - Social Media Task Force (2012 - 2014)

Member - Section Evaluation Committee (2012 - 2013)

Vice-Chair - Oncology Section (2009 - 2012)

#### American Association for Cancer Research (AACR)

Member - AACR Pancreatic Cancer Research Grants Scientific Review Committee (2012 - 2013)

#### University of North Carolina at Chapel Hill

Member - Institutional Review Board (2019 - present)

Member - Scholarship Committee, Eshelman School of Pharmacy (2015 - present)

#### Other International Organizations

- Member - Advisory Board, Grant funding, Individualizing cardiovascular disease treatment modalities in the UAE using a genomics-based approach. United Arab Emirates University (2020 - 2023)
- Member - Steering Committee of the Global Genomic Medicine Collaborative (G2MC) (2019 - present)
- Member - Planning Committee for the Eleventh Annual Chapel Hill Pharmaceutical Sciences Conference (2016 - 2017)
- Member - Scientific Advisory Board of the European Society of Pharmacogenomics and Personalized Therapy (2016 - present)
- Member - VEGF Consortium, Nancy, France (2016 - present)
- Member - Scientific Committee of the International Workshop on Clinical Pharmacology of Targeted Oncolytics (2014 - present)
- Member - Scientific Advisory Committee of the Genomic Medicine Alliance (2013 - present)
- Member - Scientific Advisory Board of the LUNGeivity Foundation (2013 - 2014)
- Member - International Scientific Advisory Council Board of the Golden Helix Institute for Medical Research (2010 - present)
- Member - Pharmacogenetic Research Network, Cancer Partnership Working Group (2007 - 2010)
- Member - Clinical Research Center Advisory Committee, University of Chicago (2005 - 2010)
- Member - Step 1 Standard Setting Panel of the National Board of Medical Examiners, United States Medical Licensing Examination (2009)
- Member - Committee on Response to Injury, Pritzker Curriculum Initiative (2007 - 2008)
- Member - Clinical Trials Review Committee, University of Chicago (2004 - 2008)
- Member - Hematology/Oncology Fellowship Selection Committee, University of Chicago (2005 - 2007)

### **Editorial Boards - present**

- Scientific Reports (2019 - present)
- PLOS ONE - Academic Editor (2018 - present)
- Clinical Pharmacology and Therapeutics (2016 - present)
- Pharmacogenetics and Genomics (2007 - present)
- Pharmacogenomics - Associate Editor (2008 - present)

### **Editorial Boards - past**

- Therapeutic Drug Monitoring (2007 - 2017)
- Journal of Clinical Oncology (2007 - 2013)

### **HONORS**

- UNC Worthy of Recognition - Instructor (2015, 2016, 2018)
- UNC Academic Excellence Award - Research (2012 - present)

Member of the Month - American Society of Clinical Pharmacology and Therapeutics - (2013)

Leon I Goldberg Young Investigator Award - American Society of Clinical Pharmacology and Therapeutics (2012)

Young Investigator Award - Cancer Research Foundation (2006)

Award for training in a foreign institution - Italian Society of Pharmacology (1998 - 1999)

Award for training in a foreign institution Italian National Research Council - (1998 - 1999)

## **BIBLIOGRAPHY (abstracts not included but available upon request)**

### **Book Chapters**

1. Cooper DN, Mitropoulou C, Brand A, Dolzan V, Fortina P, **Innocenti F**, Lee MT, Macek M, Mitropoulos K, Al-Mulla F, Prainsack B, van Schaik RH, Squassina A, Taruscio D, Vayena E, Vozikis A, Williams MS, Ylstra B, Patrinos GP. The Genomic Medicine Alliance: A Global Effort to Facilitate the Introduction of Genomics into Healthcare in Developing Nations. In Correa-Lopez C, Patrinos GP (eds). Genomic Medicine in developing and emergin economies. Elsevier/Academic Press, Burlington, CA, USA, 2018
2. Mendrinou E, Theodora Katsila T, **Innocenti F**, Squassina A, Patrinos GP. Pharmacogenomics in clinical care and drug discovery. In: "Molecular Diagnostics", Patrinos GP, Danielson P, Ansorge WJ (Ed.), Elsevier, Georgia, USA, 2016
3. Yong W-P, Soo R, **Innocenti F**. Pharmacogenomics and personalized medicines in cancer treatment. In: "Cancer Drug Design and Discovery", Neidle (Ed.), Elsevier, Georgia, USA, 2014
4. Glubb DM, Etheridge AS, Seiser E, **Innocenti F**. Liver expression quantitative trait loci (eQTL) and related approaches in pharmacogenomic studies. In: "Handbook of Pharmacogenomics and Stratified Medicines", Padmanabhan (Ed.), Elsevier Inc., 2014
5. Patel JN, Walko CM, **Innocenti F**. Pharmacogenetics and antineoplastic therapies. In: "Preventive and Predictive Genetics: Toward Personalized Medicine", Grech, Grossman (Eds.), Springer, New York, USA, 2013
6. Glubb DM, Paugh WS, van Schaik RHN, **Innocenti F**. A guide to the current web-based resources in pharmacogenomics. In: "Pharmacogenomics, Methods and Protocols" Innocenti, van Schaik (Eds). Humana Press Inc., Totowa, New Jersey, NJ, USA, 2nd edition, 2013
7. Huang RS, **Innocenti F**, Ratain MJ. Irinotecan. In: "Pharmacogenomic Testing in Current Clinical Practice", Wu, Yeo (Eds.), Springer, New York, USA, 2011
8. Ramirez J, Ratain MJ, **Innocenti F**. UGT1A1 and irinotecan treatment. In: "Cancer Pharmacogenetics". Marsh (Ed.), Springer, New York, USA, 2010
9. Perera M, **Innocenti F**. Pharmacogenetics and pharmacogenomics: impact on drug discovery and clinical care. In: "Molecular Diagnostics", Patrinos, Ansorge (Eds.), Academic Press, London, UK, 2010
10. **Innocenti F**, Iyer L, Ratain MJ. Pharmacogenomics of chemotherapeutic agents in cancer treatment. In: "Pharmacogenomics: the Search for Individualized Therapies", Licinio, Wong (Eds.), Wiley-VCH Verlag GmbH, Weinheim, Germany, 2002

### **Book Editor**

1. **Innocenti F**, Crona D. Cancer Therapy. Henry Stewart Talks Limited, London, England (2019)

2. **Innocenti F**, van Schaik RH. Pharmacogenomics: methods and protocols. Humana Press Inc., Totowa, NJ, 2nd edition, 2013
3. **Innocenti F**, Liu G. Latest thinking on efficacy and toxicity in cancer therapy. Henry Stewart Talks Limited, London, England, 2009
4. **Innocenti F**. Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response. Humana Press Inc., Totowa, New Jersey, NJ, 2008
5. **Innocenti F**. Pharmacogenomics; methods and protocols. Humana Press Inc., Totowa, New Jersey, 2005

### Original Articles

1. Quintanilha JCF, Wang J, Jiang C, Sibley AB, Etheridge AS, Shen F, Mulkey F, Patel JN, Hertz DL, Ratain MJ, Kroetz DL, Dees EC, Owzar K, McLeod HL, Schneider B, Lin D, **Innocenti F**. Bevacizumab-induced hypertension and proteinuria: A genome-wide analysis of more than 1,000 patients. (*approved by Alliance for submission*)
2. Mackintosh C, Yuan C, Ou F-S, Zhang S, Niedzwiecki D, Chang I-W, O'Neil BH, Mullen BC, Lenz H-J, Blanke CD, Venook AP, Mayer RJ, Fuchs CS, **Innocenti F**, Nixon AB, Goldberg RM, O'Reilly EM, Meyerhardt JA, Ng K. Coffee Intake and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Results from Cancer and Leukemia Group B/SWOG 80405 (Alliance). (*approved by Alliance for submission*)
3. Guercio BJ, Zhang S, Ou F-S, Venook AP, Niedzwiecki D, Lenz H-J, **Innocenti F**, Pollak M, Nixon A, Mullen BC, O'Neil BH, Shaw JE, Polite BN, Benson III AB, Atkins JN, Goldberg RM, Brown J, O'Reilly EM, Mayer RJ, Blanke CD, Fuchs CS, Meyerhardt JA. Associations of IGF-binding proteins and adiponectin with disease progression and mortality in metastatic colorectal cancer: results from CALGB (Alliance)/SWOG 80405. (*approved by Alliance for submission*)
4. Guercio BJ, Zhang S, Venook AP, Ou F-S, Niedzwiecki D, Lenz H-J, **Innocenti F**, Mullen BC, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Mayer RJ, Blanke CD, Fuchs CS, Meyerhardt JA. Body mass index, weight loss, and progression and mortality in metastatic colorectal cancer (Alliance). (*approved by Alliance for submission*)
5. Karas S, Etheridge AS, Tsakalozou E, Ramírez J, Cecchin E, van Schaik RHN, Toffoli G, Ratain MJ, Mathijssen RHJ, Forrest A, Bies RR, **Innocenti F**. Optimal Sampling Strategies for Irinotecan (CPT-11) and Its Active Metabolite (SN-38) in Cancer Patients. *AAPS J.* (*in press*)
6. Brown JC, Zhang S, Ou F-S, Venook AP, Niedzwiecki D, Lenz H-J, **Innocenti F**, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Ng K, Mayer RJ, Blanke CD, O'Reilly E, Fuchs CS, Meyerhardt JA. Diabetes and Clinical Outcome in Patients with Metastatic Colorectal Cancer: CALGB 80405 (Alliance). *JNCI Cancer Spectrum* (*in press*)
7. Etheridge A, Gallins PJ, Jima D, Broadaway KA, Ratain MJ, Schuetz E, Schadt E, Schroder A, Molony C, Zhou Y, Mohlke KL, Wright FA, **Innocenti F**. A new liver eQTL map from 1,183 individuals provides evidence for novel eQTL of drug response, metabolic and sex-biased phenotypes. *Clin Pharmacol Ther.* 2019 Dec 23. doi: 10.1002/cpt.1751. PMID: 31868224.
8. Yuan C, Sato K, Hollis BW, Zhang S, Niedzwiecki D, Ou FS, Chang IW, O'Neil BH, **Innocenti F**, Lenz HJ, Blanke CD, Goldberg RM, Venook AP, Mayer RJ, Fuchs CS, Meyerhardt JA, Ng K. Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance). *Clin Cancer Res.* 2019 Dec 15;25(24):7497-7505. PMID 31548349.

9. Guercio BJ, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, **Innocenti F**, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Sato K, Ng K, Van Blarigan E, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA. Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. *J Clin Oncol*. 2019 Aug 13; 37(29):2620-2631. PMID 31408415.
10. Lin J, Sibley A, Nixon A, **Innocenti F**, Chan C, Owzar K. fastJT: An R Package for Robust and Efficient Feature Selection for Machine Learning and Genome-Wide Association Studies. *BMC Bioinformatics*. 2019 Jun 13;20(1):333. PMID 31195980.
11. Fragoulakis V, Roncato R, Fratte CD, Ecça F, Bartsakoulia M, **Innocenti F**, Toffoli G, Cecchin E, Patrinos GP, Mitropoulou C. Estimating the Effectiveness of DPYD Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of Chemotherapy-Induced Toxicity. *Am J Hum Genet*. 2019 Jun 6;104(6):1158-1168. PMID 31155283.
12. Yuan C, Renfro L, Ambadwar PB, Ou FS, McLeod HL, **Innocenti F**, Meyerhardt JA, Wolpin BM, Goldberg RM, Grothey A, Fuchs CS, Ng K. Influence of Genetic Variation in the Vitamin D Pathway on Plasma 25-Hydroxyvitamin D<sub>3</sub> Levels and Survival Among Patients with Metastatic Colorectal Cancer. *Cancer Causes Control*. 2019 Jul;30(7):757-765. PMID 31104167.
13. Lenz H-J, Ou F-S, Venook AP, Hochster HS, Niedzwiecki D, Goldberg RM, Mayer RJ, Bertagnolli MM, Blanke CD, Zemla T, Qu X, Wirapati P, Tejpar S, **Innocenti F**, Kabbarah O. Impact of Consensus Molecular Subtype (CMS) on Survival in Patients with Metastatic Colorectal Cancer: Results from SWOG/ALLIANCE 80405. *J Clin Oncol*. 2019 Aug 1;37(22):1876-1885. PMID 31042420. (among one of 6 featured articles in the Journal for Gastrointestinal Cancer).
14. **Innocenti F**, Jiang C, Sibley AB, Denning S, Watson D, Niedzwiecki D, Hatch AJ, Hurwitz HI, Nixon AB, Furukawa Y, Kubo M, Kindler HL, McLeod HL, Ratain MJ, Owzar K. An Initial Genetic Analysis of Gemcitabine-Induced High-Grade Neutropenia in Pancreatic Cancer Patients. *Pharmacogenet Genomics*. 2019 Aug;29(6):123-131. PMID 30889042.
15. **Innocenti F**, Ou F-S, Qu X, Zemla T, Niedzwiecki D, Tam R, Mahajan S, Goldberg RM, Bertagnolli MM, Blanke CD, Sanoff H, Atkins J, Polite B, Venook AP, Lenz H-J, Kabbarah O. Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 identifies new roles of microsatellite instability and tumor mutational burden for patient outcome. *J Clin Oncol*. 2019 May 10;37(14):1217-1227. PMID 30865548. (among one of 6 featured articles in the Journal for Gastrointestinal Cancer).
16. Crona DJ, Skol AD, Leppänen VM, Glubb DM, Etheridge AS, Hilliard E, Peña CE, Peterson YK, Klauber-DeMore N, Alitalo KK, **Innocenti F**. Genetic Variants of VEGFA and FLT4 are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib. *Cancer Res*. 2019 Jan 1;79(1):231-241. PMID 30385613.
17. Gagno S, D'Andrea MR, Mansutti M, Zanusso C, Puglisi F, Dreussi E, Montico M, Bion P, Cecchin E, Iacono D, Russo S, Cinausero M, Saracchini S, Gasparini G, Sartori D, Bari M, Collovà E, Meo R, Merkabaoui G, Spagnoletti I, Pellegrino A, Gianni L, Sandri P, Cretella E, Vattemi E, Rocca A, Serra P, Fabbri MA, Benedetti G, Foghini L, Medici M, Basso U, Amoroso V, Riccardi F, Baldelli AM, Clerico M, Bonura S, Saggia C, **Innocenti F**, Toffoli G. A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated with First-Line Exemestane: Results from a Prospective Study. *Clin Breast Cancer*. 2019 Apr;19(2):137-145. PMID: 30584056.

18. **Innocenti F**, Jiang C, Sibley AB, Etheridge AS, Hatch AJ, Denning S, Niedzwiecki D, Shterev ID, Lin J, Furukawa Y, Kubo M, Kindler HL, Auman JT, Venook AP, I. Hurwitz HI, McLeod HL, Ratain MJ, Gordan R, Nixon AB, Owzar K. Genetic Variation Determines VEGF-A Plasma Levels in Cancer Patients. *Sci Rep*. 2018 Nov 5;8(1):16332. PMID 30397360.
19. Toffoli G, **Innocenti F**, Polesel J, De Mattia E, Sartor F, Fratte CD, Ecça F, Dreussi E, Palazzari E, Guardascione M, Buonadonna A, Foltran L, Garziera M, Bignucolo A, Nobili S, Mini E, Favaretto A, Berretta M, D'Andrea M, De Paoli A, Roncato R, Cecchin E. The Genotype for DPYD Risk Variants in Colorectal Cancer Patients and the Related Toxicity Management Costs in Clinical Practice. *Clin Pharmacol Ther*. 2019 Apr;105(4):994-1002. PMID 30339275.
20. **Innocenti F**, Owzar K, Jiang C, Etheridge AS, Gordân R, Sibley AB, Mulkey F, Niedzwiecki D, Glubb D, Neel N, Talamonti MS, Bentrem DJ, Seiser E, Yeh JJ, Van Loon K, McLeod H, Ratain MJ, Kindler HL, Venook AP, Nakamura Y, Kubo M, Petersen GM, Bamlet WR, McWilliams RR. The Vitamin D Receptor Gene as a Determinant of Survival in Pancreatic Cancer Patients: Genomic Analysis and Experimental Validation. *PLoS One*. 2018 Aug 14;13(8):e0202272. PMID 30107003.
21. Li M, Mulkey F, Jiang C, O'Neil BH, Schneider BP, Shen F, Friedman PN, Momozawa Y, Kubo M, Niedzwiecki D, Hochster HS, Lenz HJ, Atkins JN, Rugo HS, Halabi S, Kelly WK, McLeod HL, **Innocenti F**, Ratain MJ, Venook AP, Owzar K, Kroetz DL. Identification of a Genomic Region Between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). *Clin Cancer Res*. 2018 Oct 1;24(19):4734-4744. PMID 29871907.
22. Frayling TM, Beaumont RN, Jones SE, Yaghootkar H, Tuke MA, Ruth KS, Casanova F, West B, Locke J, Sharp S, Ji Y, Thompson W, Harrison J, Etheridge AS, Gallins PJ, Jima D, Wright F, Zhou Y, **Innocenti F**, Lindgren CM, Grarup N, Murray A, Freathy RM, Weedon MN, Tyrrell J, Wood AR. A Common Allele in FGF21 Associated with Sugar Intake Is Associated with Body Shape, Lower Total Body-Fat Percentage, and Higher Blood Pressure. *Cell Rep*. 2018 April 10;23(2):327-336. PMID 29641994.
23. Venook AP, Niedzwiecki D, Lenz HJ, **Innocenti F**, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB 3rd, Mulkerin DL, Mayer RJ, Blanke C. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. *JAMA*. 2017 Jun 20;317(23):2392-2401. PMID 28632865.
24. Sharma MR, Auman JT, Patel NM, Grilley-Olson JE, Zhao X, Moschos SJ, Parker JS, Yin X, Hayward MC, Polite BN, Marangon E, Posocco B, Toffoli G, Hayes DN, **Innocenti F**. Exceptional Chemotherapy Response in Metastatic Colorectal Cancer Associated with Hyper-Indel-Hypermutated Cancer Genome and Comutation of POLD1 and MLH1. *JCO Precis Oncol*. 2017(1):1-12.
25. Cancer Genome Atlas Research Network. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. *Cell*. 2017 Jun 15;169(7):1327-1341.e23. PMID 28622513.
26. Visvikis-Siest S, Aldasoro Arguinano AA, Stathopoulou M, Xie T, Petrelis A, Weryha G, Froguel P, Meier-Abt P, Meyer UA, Mlakar V, Ansari M, Papassotiropoulos A, Dedoussis G,



- Pan B, Bühlmann RP, Noyer-Weidner M, Dietrich PY, Van Schaik R, **Innocenti F**, März W, Bekris LM, Deloukas P. 8th Santorini Conference: Systems medicine and personalized health and therapy, Santorini, Greece, 3-5 October 2016. *Drug Metab Pers Ther*. 2017 May 24;32(2):119-127. PMID 28575488.
27. Fuchs MA, Yuan C, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, **Innocenti F**, Warren RS, Bertagnolli MM, Ogino S, Giovannucci EL, Horvath E, Meyerhardt JA, Ng K. Predicted Vitamin D Status and Colon Cancer Recurrence and Mortality in CALGB 89803 (Alliance). *Ann Oncol*. 2017 Jun 1;28(6):1359-1367. PMID 28327908.
28. Roncato R, Cecchin E, Montico M, De Mattia E, Giodini L, Buonadonna A, Solfrini V, **Innocenti F**, Toffoli G. Cost evaluation of irinotecan-related toxicities associated with the UGT1A1\*28 patient genotype. *Clin Pharmacol Ther*. 2017;102(1):123-130. PMID 28074472.
29. Toffoli G, Sharma MR, Marangon E, Posocco B, Gray E, Mai Q, Buonadonna A, Polite BN, Miolo G, Tabaro G, **Innocenti F**. Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer. *Clin Cancer Res*. 2017 Feb 15;23(4):918-924. PMID 27507617.
30. Luizon MR, Eckalbar WL, Wang Y, Jones SL, Smith RP, Laurance M, Lin L, Gallins PJ, Etheridge AS, Wright F, Zhou Y, Molony C, **Innocenti F**, Yee SW, Giacomini KM, Ahituv N. Genomic Characterization of Metformin Hepatic Response. *PLoS Genet*. 2016 Nov 30;12(11):e1006449. PubMed Central PMCID: PMC 5130177.
31. Vozikis A, Cooper DN, Mitropoulou C, Kambouris ME, Brand A, Dolzan V, Fortina P, **Innocenti F**, Lee MT, Leyens L, Macek M Jr, Al-Mulla F, Prainsack B, Squassina A, Taruscio D, van Schaik RH, Vayena E, Williams MS, Patrinos GP. Test Pricing and Reimbursement in Genomic Medicine: Towards a General Strategy. *Public Health Genomics*. 2016 Aug 9;19(6):352-363. PMID 27507617.
32. Li M, Seiser EL, Baldwin RM, Ramirez J, Ratain MJ, **Innocenti F**, Kroetz DL. ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia. *Pharmacogenomics J*. 2016 Nov 15. PubMed Central PMCID: PMC5432414.
33. Zhou K, Yee SW, Seiser EL, van Leeuwen N, Tavendale R, Bennett AJ, Groves CJ, Coleman RL, van der Heijden AA, Beulens JW, de Keyser CE, Zaharenko L, Rotroff DM, Out M, Jablonski KA, Chen L, Javorský M, Židzik J, Levin AM, Williams LK, Dujic T, Semiz S, Kubo M, Chien HC, Maeda S, Witte JS, Wu L, Tkáč I, Kooy A, van Schaik RH, Stehouwer CD, Logie L; MetGen Investigators.; DPP Investigators.; ACCORD Investigators, Sutherland C, Klovin J, Pirags V, Hofman A, Stricker BH, Motsinger-Reif AA, Wagner MJ, **Innocenti F**, Hart LM, Holman RR, McCarthy MI, Hedderson MM, Palmer CN, Florez JC, Giacomini KM, Pearson ER. Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. *Nat Genet*. 2016 Sep;48(9):1055-9. PubMed Central PMCID: PMC 5007158.
34. Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, **Innocenti F**. Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance). *J Clin Oncol*. 2016 Sep 1;34(25):3047-53. PubMed Central PMCID: PMC 5012711. (Among best articles in *JCO* for 2016).

35. Hatch AJ, Sibley AB, Starr MD, Brady JC, Jiang C, Jia J, Bowers DL, Pang H, Owzar K, Niedzwiecki D, **Innocenti F**, Venook AP, Hurwitz HI, Nixon AB; Alliance for Clinical Trials in Oncology. Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). *Cancer Med*. 2016 Sep;5(9):2249-60. PubMed Central PMCID: PMC 5055181.
36. Dickler MN, Barry WT, Cirrincione CT, Ellis MJ, Moynahan ME, **Innocenti F**, Hurria A, Rugo HS, Lake DE, Hahn O, Schneider BP, Tripathy D, Carey LA, Winer EP, Hudis CA. Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). *J Clin Oncol*. 2016 Aug 1;34(22):2602-9. PubMed Central PMCID: PMC 5012690.
37. Crona DJ, Ramirez J, Qiao W, de Graan AJ, Ratain MJ, van Schaik RH, Mathijssen RH, Rosner GL, **Innocenti F**. Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study. *Pharmacogenomics J*. 2016 Feb;16(1):54-9. PubMed Central PMCID: PMC 4729652.
38. Pellé L, Cipollini M, Tremmel R, Romei C, Figlioli G, Gemignani F, Melaiu O, De Santi C, Barone E, Elisei R, Seiser E, **Innocenti F**, Zanger UM, Landi S. Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinoma. *Arch Toxicol*. 2015 Dec;90(12):3099-3109. PMID 26783003.
39. Chen S, Villeneuve L, Jonker D, Couture F, Laverdière I, Cecchin E, **Innocenti F**, Toffoli G, Lévesque E, Guillemette C. ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients. *Pharmacogenet Genomics*. 2015 Dec;25(12):573-83. PMID 26352872.
40. Chen S, Laverdiere I, Tourancheau A, Jonker D, Couture F, Cecchin E, Villeneuve L, Harvey M, Court MH, **Innocenti F**, Toffoli G, Lévesque E, Guillemette C. A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patients. *Pharmacogenomics J*. 2015 Dec;15(6):513-20. PMID 25778466.
41. Glubb DM, Paré-Brunet L, Jantus-Lewintre E, Jiang C, Crona D, Etheridge AS, Mirza O, Zhang W, Seiser EL, Rzyman W, Jassem J, Auman T, Hirsch FR, Owzar K, Camps C, Dziadziuszko R, **Innocenti F**. Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I-III Non-Small-Cell Lung Cancer. *J Thorac Oncol*. 2015 Jul;10(7):1067-75. PubMed Central PMCID: PMC 4494119.
42. Wolpin BM, Rizzato C, Kraft P, Kooperberg C, Petersen GM, Wang Z, Arslan AA, Beane-Freeman L, Bracci PM, Buring J, Canzian F, Duell EJ, Gallinger S, Giles GG, Goodman GE, Goodman PJ, Jacobs EJ, Kamineni A, Klein AP, Kolonel LN, Kulke MH, Li D, Malats N, Olson SH, Risch HA, Sesso HD, Visvanathan K, White E, Zheng W, Abnet CC, Albanes D, Andreotti G, Austin MA, Barfield R, Basso D, Berndt SI, Boutron-Ruault MC, Brotzman M, Büchler MW, Bueno-de-Mesquita HB, Bugert P, Burdette L, Campa D, Caporaso NE, Capurso G, Chung C, Cotterchio M, Costello E, Elena J, Funel N, Gaziano JM, Giese NA, Giovannucci EL, Goggins M, Gorman MJ, Gross M, Haiman CA, Hassan M, Helzlsouer KJ, Henderson BE, Holly EA, Hu N, Hunter DJ, **Innocenti F**, Jenab M, Kaaks R, Key TJ, Khaw KT, Klein EA, Kogevinas M, Krogh V, Kupcinskis J, Kurtz RC, LaCroix A, Landi MT, Landi S, Le Marchand L, Mambrini A, Mannisto S, Milne RL, Nakamura Y, Oberg AL, Owzar K, Patel AV, Peeters PH, Peters U, Pezzilli R, Piepoli A, Porta M, Real FX, Riboli E, Rothman N, Scarpa A, Shu XO, Silverman DT, Soucek P, Sund M, Talar-Wojnarowska R, Taylor PR, Theodoropoulos GE, Thornquist M, Tjønneland A, Tobias GS, Trichopoulos D,

- Vodicka P, Wactawski-Wende J, Wentzensen N, Wu C, Yu H, Yu K, Zeleniuch-Jacquotte A, Hoover R, Hartge P, Fuchs C, Chanock SJ, Stolzenberg-Solomon RS, Amundadottir LT. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. *Nat Genet.* 2014 Sep;46(9):994-1000. PubMed Central PMCID: PMC 4191666.
43. Van Loon K, Owzar K, Jiang C, Kindler HL, Mulcahy MF, Niedzwiecki D, O'Reilly EM, Fuchs C, **Innocenti F**, Venook AP; Alliance for Clinical Trials in Oncology. 25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance). *J Natl Cancer Inst.* 2014 Aug 6;106(8). PubMed Central PMCID: PMC 4155431.
44. **Innocenti F**, Schilsky RL, Ramírez J, Janisch L, Undevia S, House LK, Das S, Wu K, Turcich M, Marsh R, Karrison T, Maitland ML, Salgia R, Ratain MJ. Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. *J Clin Oncol.* 2014 Aug 1;32(22):2328-34. PubMed Central PMCID: PMC 4105486.
45. De Re V, Caggiari L, De Zorzi M, Talamini R, Racanelli V, D' Andrea M, Buonadonna A, Zagonel V, Cecchin E, **Innocenti F**, Toffoli G. Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy. *PLoS One.* 2014 Jan 31;9(1):e84940. PubMed Central PMCID: PMC 3908861.
46. Ramírez J, Kim TW, Liu W, Myers J, Mirkov S, Owzar K, Watson D, Mulkey F, Gamazon ER, Xia K, Stock W, Undevia S, **Innocenti F**, Ratain MJ. A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469. *Pharmacogenet Genomics*, 2014;24:129-32. PubMed Central PMCID: PMC 3901533.
47. Paré-Brunet L, Glubb D, Evans E, Berenguer-Llergo T, Etheridge A, Skol A, Di Rienzo A, Duan D, Gamazon E, **Innocenti F**. Discovery and functional assessment of gene variants in the vascular endothelial growth factor pathway. *Human Mutat*, 2014;35:227-35. PubMed Central PMCID: PMC 3935516.
48. Gamazon ER, **Innocenti F**, Wei R, Wang L, Zhang M, Mirkov S, Ramírez J, Huang RS, Cox NJ, Ratain MJ, Liu W. A genome-wide integrative study of microRNAs in human liver. *BMC Genomics*, 2013 Jun 13;14:395. PubMed Central PMCID: PMC 3710218.
49. **Innocenti F**, Ramírez J, Obel J, Xiong J, Mirkov S, Chiu Y, Katz DA, Carr RA, Zhang W, Das S, Adjei A, Moyer AM, Chen PX, Krivoschik A, Medina D, Gordon GB, Ratain MJ, Sahelijo L, Weinshilboum RM, Fleming GF, Bhathena A. Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751. *Pharmacogenet Genomics*, 2013;374-81. PubMed Central PMCID: PMC 3858967.
50. Levesque E, Belanger AS, Harvey M, Couture F, Jonker D, **Innocenti F**, Cecchin E, Toffoli G, Guillemette C. Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan (FOLFIRI)-based regimens. *J Pharmacol Exp Ther*, 2013;345:95-101. PubMed Central PMCID: PMC 3920089.
51. Cecchin E, D'Andrea M, Lonardi S, Zanusso C, Pella N, Errante D, De Mattia E, Polesel J, **Innocenti F**, Toffoli G. A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. *Pharmacogenomics J*, 2012;13:403-9. PubMed Central PMCID: PMC 3859145.

52. **Innocenti F**, Owzar K, Cox NJ, Evans P, Kubo M, Zembutsu H, Jiang C, Hollis D, Mushiroda T, Li L, Friedman P, Wang L, Glubb DM, Hurwitz HI, Giacomini KM, McLeod HL, Goldberg RM, Schlisky R, Kindler HL, Nakamura Y, Ratain MJ. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. *Clin Cancer Res*, 2012;18:577-84. PubMed Central PMCID: PMC 843412624.
53. Ramírez J, Wu K, Janisch L, Karrison T, House LK, **Innocenti F**, Cohen EE, Ratain MJ. The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients. *Cancer Chemother Pharmacol*, 2011;68:1629-32. PubMed Central PMCID: PMC 3259680.
54. Biondo P, Hattinger CM, **Innocenti F**, Talamini R, Alberghini M, Scotlandi K, Zanusso C, Serra M, Toffoli G. Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy. *Pharmacogenomics J*, 2011;12:476-83. PubMed Central PMCID: PMC 3935514.
55. Glubb DM, Cerri E, Giese A, Zhang W, Mirza O, Thompson EE, Chen P, Das S, Jassem J, Rzyman W, Lingen MW, Salgia R, Hirsch FR, Dziadziuszko R, Ballmer-Hofer K, **Innocenti F**. Novel functional germline variants in the vascular endothelial growth factor receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. *Clin Cancer Res*, 2011;17:5257-67. PubMed Central PMCID: PMC 3156871.
56. **Innocenti F**, Cooper GM, Stanaway IB, E Gamazon, Smith JD, Mirkov S, Ramirez J, Liu W, Lin YS, Moloney C, Aldred SF, Trinklein ND, Schuetz EG, Nickerson DA, Thummel KE, Rieder MJ, Rettie AE, Ratain MJ, Cox NJ, Brown CD. Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue. *PLoS Genet*, 2011;7:e1002078. PubMed Central PMCID: PMC 3102751.
57. O'Donnell PH, Artz AS, Undevia SD, Pai RK, del Cerro P, Horowitz S, Godley LA, Hart J, **Innocenti F**, Larson RA, Odenike OM, Stock W, van Besien K. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplantation: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. *Leuk Lymphoma*, 2010 Dec;51:2240-9. PubMed Central PMCID: PMC 4477684.
58. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, **Innocenti F**, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM for the Cancer and Leukemia Group B. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: A phase III trial of the cancer and leukemia group B (CALGB 80303). *J Clin Oncol*, 2010;28:3617-22. PubMed Central PMCID: PMC 2917317.
59. Toffoli G, Cecchin E, Gasparini G, D'Andrea M, Azzarello G, Basso U, Mini E, Pessa S, De Mattia E, Lo Re G, Buonadonna A, Nobili S, De Paoli P, **Innocenti F**. Genotype-driven phase I study of irinotecan administered in combination with 5-fluorouracil/leucovorin (FOLFIRI) in metastatic colorectal cancer patients. *J Clin Oncol*, 2010 Feb 10;28:866-71. PubMed Central PMCID: PMC 4872310.
60. **Innocenti F**, Kroetz DL, Schuetz E, Dolan ME, Ramírez J, Relling M, Chen P, Das S, Rosner GL, Ratain MJ. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacogenetics. *J Clin Oncol*, 2009;27:2604-14. PubMed Central PMCID: PMC 2690389

61. Yong WP, Kim TW, Undevia SD, **Innocenti F**, Ratain MJ. R(+)-XK469 inhibits hydroxylation of S-warfarin by CYP2C9. *Eur J Cancer*, 2009;45:1904-8. PubMed Central PMCID: PMC 2758059.
62. Cecchin E, **Innocenti F**, D'Andrea M, Corona G, De Mattia E, Biason P, Buonadonna A, De Paoli P, Toffoli G. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with FOLFIRI. *J Clin Oncol*, 2009 May 20;27:2457-65. PMID 19364970.
63. **Innocenti F**, Mirkov S, Nagasubramanian R, Ramirez J, Liu W, Bleibel WK, Shukla SJ, Hennessy K, Rosner GL, Cook EH, Dolan ME, Ratain MJ. The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds. *Cancer Chemother Pharmacol*, 2009;63:881-7. PubMed Central PMCID: PMC 2731557.
64. Hoskins JM, Rosner GL, Ratain MJ, McLeod HL, **Innocenti F**. Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high dose irinotecan. *Pharmacogenomics*, 2009; 10:1139-46. PubMed Central PMCID: PMC 2748108.
65. Krishnaswamy S, Janamanchi V, Soulii L, Seiwert TY, Nallasura V, Loganathan S, Kanteti R, Ramnath N, Szeto L, **Innocenti F**, Xin Y, Nicolae DL, Ma PC, Ouyang Z, Liang J, Minna J, Kozloff M, Natarajan V, Ferguson MK, Wang Y, Sattler M, Garcia JN, Vokes EE, Husain AN, Jagadeeswaran R, Salgia R. Ethnic differences and functional analysis of c-met mutations in lung cancer. *Clin Cancer Res*, 2009;15:5714-23. PubMed Central PMCID: PMC 2767337.
66. Ramirez J, Mirkov S, Zhang W, Chen PX, Das S, Liu W, Ratain MJ, **Innocenti F**. Hepatocyte nuclear factor-1 alpha regulates UGT1A1, UGT1A9, and UGT2B7 mRNA expression in the liver. *Pharmacogenomics J*, 2008 Apr 8; 8:152-61. PMID 17440429.
67. Corona G, Vaccher E, Sandron S, Sartor I, Tirelli U, **Innocenti F**, Toffoli G. Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma. *Clin Pharmacol Ther*, 2008 Apr; 83:601-6. PMID 17713471.
68. Rosner GL, Panetta JC, **Innocenti F**, Ratain MJ. Pharmacogenetic pathway analysis of irinotecan. *Clin Pharmacol Ther*, 2008; 84:393-402. PubMed Central PMCID: PMC 2759399.
69. **Innocenti F**, Liu W, Fackenthal D, Ramirez J, Chen P, Xin Ye, Wu X, Zhang W, Mirkov S, Das S, Cook EH, Ratain MJ. Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene. *Pharmacogenet Genomics*, 2008;18:683-97. PubMed Central PMCID: PMC 2680356.
70. Undevia SD, **Innocenti F**, Ramirez J, House L, Desai AA, Skoog LA, Singh DA, Karrison T, Kindler HL, Ratain MJ. A phase I and pharmacokinetic study of the quinoxaline antitumor agent R(+)-XK469 in patients with advanced solid tumors. *Eur J Cancer* 2008; 44:1684-92. PubMed Central PMCID: PMC 2731567.
71. Liu W, Wu X, Zhang W, Montenegro RC, Fackenthal DL, Spitz JA, Huff LM, **Innocenti F**, Das S, Cook EH, Cox NJ, SE Bates, Ratain MJ. Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. *Clin Cancer Res*, 2007 Nov 15;13:6788-95. PMID 18006781.

72. Mirkov S, Komoroski BJ, Ramírez J, Yoder Graber A, Ratain MJ, Strom SC, **Innocenti F**. Effects of green tea compounds on irinotecan metabolism. *Drug Metab Dispos*, 2007 Feb; 35:228-33. PMID 17108060.
73. Yoder Graber A, Ramírez J, Zhang W, **Innocenti F**, Ratain MJ. *UGT1A1*\*28 genotype affects the in vitro glucuronidation of thyroxine in human livers. *Pharmacogenet Genomics*, 2007 Aug;17:619-27. PMID 17622938.
74. Ramchandani RP, Wang Y, Booth BP, Ibrahim A, Johnson J, Rahman A, Mehta M, **Innocenti F**, Ratain MJ, Gobburu JVS. The role of SN-38 exposure, *UGT1A1*\*28 polymorphisms and baseline bilirubin levels in predicting severe irinotecan toxicity. *J Clin Pharmacol* 2007 Jan;47:78-86. PMID 17192505.
75. Ramirez J, Liu W, Mirkov S, Desai AA, Chen P, Das S, **Innocenti F**, Ratain MJ. Lack of association between common polymorphisms in UGT1A9 and gene expression and activity. *Drug Metab Dispos*, 2007 Dec;35:2149-53. PMID 17761781.
76. Yong WP, Desai AA, **Innocenti F**, Shepard D, Kobayashi K, House L, Fleming GF, Vogelzang NJ, Schilsky R, Ratain MJ. Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer. *Cancer Chemother Pharmacol*, 2007 Nov;60:811-9. PMID 17308893.
77. Zhang W, Liu W, **Innocenti F**, Ratain MJ. Searching for tissue-specific expression pattern-linked nucleotides of UGT1A isoforms. *PLoS One*, 2007 Apr 25;2:e396. PMID 17460763.
78. Ramírez J, Komoroski BJ, Mirkov S, Yoder Graber A, Fackenthal DL, Schuetz EG, Das S, Ratain MJ, **Innocenti F**, Strom SC. Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytes. *Pharmacogenet Genomics*, 2006 Feb;16:79-86. PMID 16424820.
79. Liu W, **Innocenti F**, Wu MH, Desai AA, Dolan ME, Cook EH, Ratain MJ. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. *Cancer Res*, 2005 Jan 1;65:46-53. PMID 15665278.
80. **Innocenti F**, Danesi R, Natale G, Bocci G, Del Tacca M. 5-Fluorouracil catabolism to 5-fluoro-5, 6-dihydrofluorouracil is reduced by acute liver impairment in mice. *Toxicol Appl Pharmacol* 2005 Mar 1;203:106-13. PMID 15710171.
81. **Innocenti F**, Liu W, Chen P, Desai AA, Das S, Ratain MJ. Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. *Pharmacogenet Genomics*, 2005 May;15:295-301. PMID 15864130.
82. Yong WP, Ramirez J, **Innocenti F**, Ratain MJ. Effect of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes. *Clin Cancer Res*, 2005 Sep 15;11:6699-704. PMID 1616450.
83. Desai A, **Innocenti F**, DeMario M, Shepard D, Ramirez J, Fleming G, Ratain MJ. A phase I trial of pharmacokinetic modulation of carboxyamido-triazole (CAI) with ketokonazole in advanced cancer patients. *Cancer Chemother Pharmacol*, 2004 Nov;54:377-84. PMID 15235824.
84. **Innocenti F**, Undevia SD, Ramírez J, Mani S, Schilsky RL, Vogelzang NJ, Prado M, Ratain MJ. A phase I trial of pharmacological modulation of irinotecan with cyclosporine A and phenobarbital. *Clin Pharmacol Ther*, 2004 Nov;76:490-502. PMID 15536463.

85. **Innocenti F**, Undevia SD, Iyer L, Chen P, Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM, Vokes EE, Ratain MJ. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. *J Clin Oncol*, 2004 April 15;22:1382-8. PMID 15007088.
86. Ramírez J, **Innocenti F**, Schuetz EG, Flockhart DA, Relling MV, Santucci R, Ratain MJ. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. *Drug Metab Dispos*, 2004 Sep;32:930-6. PMID 15319333.
87. Liu W, **Innocenti F**, Das S, Chen P, Cook EH, Ratain MJ. Interethnic difference in the allelic distribution of human epidermal growth factor receptor (EGFR) intron 1 polymorphism. *Clin Cancer Res*, 2003 Mar;9:1009-12. PMID 12631599.
88. Bengala C, Danesi R, Guarneri V, Pazzagli I, Donati S, Favre C, Fogli S, Biadi O, **Innocenti F**, Del Tacca M, Mariani M, Conte PF. High-dose consolidation chemotherapy with idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. *Bone Marrow Transplant*, 2003 Feb;31:275-80. PMID 12621462.
89. Sawyer MB, **Innocenti F**, Das S, Cheng C, Ramirez J, Pantle-Fisher FH, Wright C, Badner J, Pei D, Boyett JM, Cook EH, Ratain MJ. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. *Clin Pharmacol Ther*, 2003 Jun;73:566-74. PMID 12811366.
90. Toffoli G, Russo A, **Innocenti F**, Corona G, Tumolo S, Sartor F, Mini E, Boiocchi M. Effect of methylenetetrahydrofolate reductase 677C→T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. *Int J Cancer*, 2003 Jan 20;103:294-9. PMID 12471611.
91. **Innocenti F**, Grimsley C, Das S, Ramírez J, Cheng C, H Kuttab-Boulos, Ratain MJ, Di Rienzo A. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. *Pharmacogenetics*, 2002 Dec;12:725-33. PMID 12464801.
92. Bocci G, Danesi R, Allegrini A, **Innocenti F**, Di Paolo A, Falcone A, Conte PF, Del Tacca M. Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5, 6-dihydrouracil. A case report. *Eur J Clin Pharmacol*, 2002 Dec;58:593-5. PMID 12602342.
93. Ramirez J, Iyer L, Journault K, Belanger P, **Innocenti F**, Ratain MJ, Guillemette C. In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes. *Pharm Res*, 2002 May;19:588-94. PMID 12069159.
94. Danesi R, **Innocenti F**, Fogli S, Gennari A, Baldini E, Di Paolo A, Salvadori B, Bocci G, Conte PF, Del Tacca M. Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. *Br J Clin Pharmacol*, 2002 May;53:508-18. PMID 11994057.
95. Bengala C, Pazzagli I, **Innocenti F**, Donati S, Favre C, Menconi MC, Greco F, Danesi R, Orlandini C, Guarneri V, Del Tacca M, Conte PF. High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC). *Ann Oncol*, 2001 Jan; 12:69-74. PMID 11249051.

96. **Innocenti F**, Iyer L, Ramirez J, Green MD, Ratain MJ. Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7 (UGT2B7). *Drug Metab Dispos*, 2001 May; 29:686-92. PMID 11302935.
97. Di Paolo A, Danesi R, Nardini D, Bocci G, **Innocenti F**, Fogli S, Barachini S, Marchetti A, Bevilacqua G, Del Tacca M. Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumor cells. *Br J Cancer*, 2000 Feb;82:905-12. PMID 10732765.
98. Bocci G, Danesi R, Di Paolo A, **Innocenti F**, Allegrini G, Falcone A, Melosi A, Battistoni M, Barsanti G, Conte PF, Del Tacca M. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. *Clin Cancer Res*, 2000 Aug; 6:3032-7. PMID 10955781.
99. **Innocenti F**, Danesi R, Favre C, Nardi M, Menconi M, Di Paolo A, Bocci G, Fogli S, Barbara C, Barachini S, Casazza G, Macchia P, Del Tacca M. Variable correlation between 6-mercaptopurine metabolites in erythrocytes and hematological toxicity: implications for drug monitoring in children with acute lymphoblastic leukemia. *Ther Drug Monitor*, 2000 Aug;22:375-82. PMID 10942174.
100. **Innocenti F**, Stadler WM, Iyer L, Ramirez J, Vokes EE, Ratain MJ. Metabolism of flavopiridol in cancer patients is associated with the occurrence of diarrhea. *Clin Cancer Res*, 2000 Sep;6:3400-5. PMID 10999721.
101. Bocci G, Danesi R, Benelli U, **Innocenti F**, Di Paolo A, Fogli S, Del Tacca M. Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo. *Cancer Chemother Pharmacol*, 1999;43:205-12. PMID 9923550.
102. Fogli S, Danesi R, **Innocenti F**, Di Paolo A, Bocci G, Barbara C, Del Tacca M. An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma. *Ther Drug Monitor*, 1999 Jun;21:367-75. PMID 10365655.
103. **Innocenti F**, Danesi R, Bocci G, Fogli S, Di Paolo A, Del Tacca M. Metabolism of 6-mercaptopurine in erythrocytes, liver and kidney of rats during multiple-dose regimens. *Cancer Chemother Pharmacol*, 1999;43:133-40. PMID 9923818.
104. Conte PF, Baldini E, Gennari A, Michelotti A, Salvadori B, Tibaldi C, Danesi R, **Innocenti F**, Gentile A, Dell'Anna R, Biadi O, Mariani M, Del Tacca M. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. *J Clin Oncol*, 1997 Jul;15:2510-7. PMID 9215819.
105. Di Paolo A, Danesi R, **Innocenti F**, Bocci G, Nardini D, Fogli S, Pollina L, Rossi B, Del Tacca M. Chronic administration of suramin induces neurotoxicity in rats. *J Neurol Sci*, 1997 Nov 25;152:125-31. PMID 9415531.
106. **Innocenti F**, Danesi R, Di Paolo A, Loru B, Favre C, Nardi M, Bocci G, Nardini D, Macchia P, Del Tacca M. Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate. *Cancer Chemother Pharmacol*, 1996;37:409-14. PMID 8599862.
107. Di Paolo A, Bocci G, **Innocenti F**, Agen C, Nardini D, Danesi R, Del Tacca M. Inhibitory effect of the somatostatin analogue SMS 201-995 and cytokines on the



proliferation of human colon adenocarcinoma cell lines. *Pharmacol Res*, 1995 Sep;32:135-9. PMID 8745343.

108. **Innocenti F**, Danesi R, Di Paolo A, Agen C, Nardini D, Bocci G, Del Tacca M. Plasma and tissue disposition of paclitaxel (Taxol) after intraperitoneal administration in mice. *Drug Metab Dispos*, 1995 Jul;23:713-7. PMID 7587959.
109. Pinna A, Agen C, Di Paolo A, **Innocenti F**, Nardini D, Danesi R, Del Tacca M. Dissociation between in vitro cytotoxicity and in vivo cardiotoxicity of two new anthracyclines: 3'-deamino-3'-(2-methoxy-4-morpholinyl) doxorubicin and 4'-deoxy-4'-iodo-doxorubicin. *J Environ Pathol Toxicol Oncol* 1994;13:25-31. PMID 7823290.

### Invited Reviews

1. Stathopoulou MG, Xie T, Ruggiero D, Chatelin J, Rancier M, Weryhal G, Kurth MJ, Arguinano AA, Gorenjak V, Petrelis AM, Dagher G, Dedoussis G, Deloukas P, Lamont J, Marc J, Simmaco M, van Schaik RHN, **Innocenti F**, Merlin JL, Schneider J, Alizadeh BZ, Ciullo M, Seshadri S, Visvikis-Siest S. A transnational collaborative network dedicated to the study and applications of the Vascular Endothelial Growth Factor-A in medical practice: The VEGF Consortium. *Clin Chem Lab Med*. 2018 Mar 28;56(4):83-86. PMID 29087954.
2. Dong OM, Rachel M. Howard RM, Church R, Cottrell M, Forrest A, **Innocenti F**, Mosedale M, Kashuba A, Gonzalez D, Wiltshire T. Pharmacy in the Era of Precision Medicine: Challenges and Solutions for Future Pharmacy Practice. *Am J Pharm Educ*. 2018 Aug;82(6):6652. PMID 30181675.
3. Milano G, **Innocenti F**, Lacarelle B, Ciccolini J. "No pain, No gain" still true with immunotherapy: When the finger shows the moon, look at the moon! *Crit Rev Oncol Hematol*. 2018 Jul;127:1-5.
4. **Innocenti F**. Bringing a genomic perspective to the safety of drug treatment in oncology. *F1000Res*. 2017 Mar 29;6. pii: F1000 Faculty Rev-385. PubMed Central PMCID: PMC5373416.
5. Seiser EL, **Innocenti F**. Hidden Markov Model-Based CNV Detection Algorithms for Illumina Genotyping Microarrays. *Cancer Inform*, 2015;13(Suppl 7):77-83. PubMed Central PMCID: PMC4310714.
6. Cooper DNJ, Brand A, Dolzan V, Fortina P, **Innocenti F**, Lee MTA, Macek MJ, Al-Mulla F, Prainsack B, Squassina A, Vayena E, Vozikis A, Williams MS, Patrinos GP. Bridging genomics research between developed and developing countries: The Genomic Medicine Alliance. *Personal Med*, 2014;11(7):615-623.
7. Gillis NK, **Innocenti F**. Evidence required to demonstrate clinical utility of pharmacogenetic testing: the debate continues. *Clin Pharmacol Ther*, 2014;96:655-7.
8. Gillis NK, Patel JN, **Innocenti F**. Clinical implementation of germline cancer pharmacogenetic variants during the next-generation sequencing era. *Clin Pharmacol Ther*, 2013;95:269-80. PubMed Central PMCID: PMC 4128332.
9. Patel JN, McLeod HL, **Innocenti F**. Implications of genome-wide association studies in cancer therapeutics. *Br J Cancer*, 2013;76:370-80. PubMed Central PMCID: PMC 3769665.
10. Glubb DM, Dholakia N, **Innocenti F**. Liver expression quantitative trait loci: a foundation for pharmacogenomic research. *Front Genet*, 2012;3:153. PubMed Central PMCID: PMC 3418580.

11. Soo RA, Yong WP, **Innocenti F**. Systemic therapies for pancreatic cancer - the role of pharmacogenetics. *Curr Drug Targets*, 2012;13:811-28. PubMed Central PMCID: PMC 3795429.
12. Crona D, **Innocenti F**. Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy? *Biomark Med*, 2012;6:349-62. PubMed Central PMCID: PMC 3704209.
13. Dupuis R, Yuen A, **Innocenti F**. The influence of UGT polymorphisms as biomarkers in solid organ transplantation. *Clin Chim Acta*, 2012;413:1318-25. PubMed Central PMCID: PMC 3795433.
14. Mitropoulos K, **Innocenti F**, van Schaik RH, Lezhava A, Tzimas G, Kollia P, Macek M, Fortina P, Patrinos GP. Institutional profile: Golden Helix Institute of Biomedical Research: interdisciplinary research and educational activities in pharmacogenomics and personalized medicine. *Pharmacogenomics*, 2012;13:387-92. PubMed Central PMCID: PMC 3858958.
15. Peng Soh TI, Peng Yong W, **Innocenti F**. Recent progress and clinical importance of pharmacogenetics in cancer therapy. *Clin Chem Lab Med* 2011; 49:1621-32. PubMed Central PMCID: PMC 3858908.
16. **Innocenti F**, Cox NJ, Dolan ME. The use of genomic information to optimize cancer chemotherapy. *Semin Oncol*, 2011; 38:186-95. PubMed Central PMCID: PMC 3076508
17. Glubb DM, **Innocenti F**. Mechanisms of genetic regulation in gene expression: examples from drug metabolizing enzyme and transporter genes. *Wiley Interdiscip Rev Syst Biol Med*, 2010;3:299-313.
18. Ramirez J, Ratain MJ, **Innocenti F**. Uridine 5'-diphospho-glucuronosyltransferase (UGT) genetic polymorphisms and response to cancer chemotherapy. *Future Oncol*, 2010;6:563-85. PubMed Central: PMCID PMC 3102300.
19. Wong A, Soo R, Yong W-P, **Innocenti F**. Clinical pharmacology and pharmacogenetics of gemcitabine. *Drug Metab Rev*, 2009; 41:77-88.
20. Perera MA, **Innocenti F**, Ratain MJ. Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet? *Pharmacotherapy*. 2008; 28(6):755-68.
21. Yong W-P, **Innocenti F**. Translation of pharmacogenetic knowledge into cancer therapeutics. *Clin Adv Hematol Oncol*, 2007;5:698-706
22. **Innocenti F**. Challenges in the development and use of pharmacogenomic markers in oncology. *J Support Oncol*, 2007;5:15-6
23. Kim TW, **Innocenti F**. Role of UGT1A1\*6 in irinogenetics in Asians. *Per Med*. 2007 Nov;4(4):431-434. PMID 29793274.
24. Kim TW, **Innocenti F**. Insights, challenges and future directions in irinogenetics. *Ther Drug Monitor*, 2007;29:265-70
25. Cerri E, Falcone A, **Innocenti F**. Cancer pharmacogenomics: germ line DNA, tumor DNA, or both? *Curr Pharmacogenomics*, 2007;5:87-101
26. **Innocenti F**, Ratain MJ. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. *Pharmacogenomics*, 2006;7:1211-21
27. Yong W-P, **Innocenti F**, Ratain MJ. The role of pharmacogenetics in cancer therapeutics. *Br J Clin Pharmacol*, 2006;62:35-46
28. **Innocenti F**, Ratain MJ. "Irinogenetics" and UGT1A1: from genotypes to haplotypes. *Clin Pharmacol Ther*, 2004;75:495-500

29. Desai AA, **Innocenti F**, Ratain MJ. Pharmacogenomics: road to anticancer therapeutics nirvana? *Oncogene Rev*, 2003;22:6621-8
30. **Innocenti F**, Ratain MJ. Irinotecan treatment in cancer patients with *UGT1A1* polymorphisms. *Oncology*, 2003; 17:52-5
31. Desai AA, **Innocenti F**, Ratain MJ. *UGT* pharmacogenomics: Implications for cancer risk and cancer therapeutics. *Pharmacogenetics*, 2003;13:517-23
32. Nagasubramanian R, **Innocenti F**, Ratain MJ. Pharmacogenetics in cancer treatment. *Ann Rev Med*, 2003;54:437-52
33. **Innocenti F**, Ratain MJ. Update on pharmacogenetics in cancer chemotherapy. *Eur J Cancer*, 2002;38:639-44
34. **Innocenti F**, Iyer L, Ratain MJ. Pharmacogenetics of anti-cancer agents: lessons from amonafide and irinotecan. *Drug Metab Dispos*, 2001;29:596-600
35. **Innocenti F**, Iyer L, Ratain MJ. Pharmacogenetics: a tool for individualizing antineoplastic therapy. *Clin Pharmacokin*, 2000;39:315-25

### **Invited Editorials**

1. **Innocenti F**. *DPYD* variants to predict 5-FU toxicity: the ultimate proof. *J Nat Cancer Inst*, 2015;106(12). PubMed PMID: 25381394.
2. **Innocenti F**. Evidence for clinical utility of pharmacogenetic testing. *Clin Pharmacol Ther* 2014 (podcast).
3. Glubb DM, **Innocenti F**. Architecture of pharmacogenomic associations: structures with functional foundations or castles made of sand? *Pharmacogenomics*, 2013;14:1-4. PubMed Central: PMCID: PMC 23252941.
4. **Innocenti F**. Moving away from candidate genes: a 'genome-wise' discovery of gemcitabine myelotoxicity. *Pharmacogenomics*, 2012;13:1113-4. PubMed Central: PMCID PMC 4131678.
5. **Innocenti F**. One SNP for both cancer risk and survival in colorectal cancer: two for the price of one? *Pharmacogenomics*, 2012;13:1114. PubMed Central: PMCID PMC 4128334.
6. Ratain MJ, **Innocenti F**. Individualizing dosing of irinotecan. *Clin Cancer Res*, 2010;16:371-2.
7. **Innocenti F**, Schilsky LR. Translating the cancer genome into clinically useful tools and strategies. *Dis Model Mech*, 2009;2:426-9.
8. Toffoli G, **Innocenti F**. MTHFR and ALL risk: a challenge. *Leuk Lymphoma*, 2006; 47:1203-4.
9. **Innocenti F**, Vokes EE, Ratain MJ. Irinogenetics: what is the right "star"? *J Clin Oncol*, 2006;24:2221-4.

### **Letters to the Editor**

1. **Innocenti F**, Ou FS, Qu X, Zemla T, Niedzwiecki D, Tam R, Mahajan S, Goldberg RM, Bertagnolli MM, Blanke CD, Sanoff H, Atkins J, Polite B, Venook AP, Lenz HJ, Kabbarah O. Reply to S. Sorcher. *J Clin Oncol*, 2019 Sep 1;37(25):2291-2293. PMID: 31268798.
2. Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD,

- Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, **Innocenti F**. Reply to L. Casadaban et al. *J Clin Oncol*, 2017 Apr 20;35(12):1373-1374. PMID: 28113023.
3. Liu W, **Innocenti F**, Ratain MJ. Linkage Disequilibrium Across the *UGT1A* Locus Should not be Ignored in Association Studies of Cancer Susceptibility. Correspondence re: Wang Y, et al. UDP-glucuronosyltransferase 1A7 genetic polymorphisms are associated with hepatocellular carcinoma in Japanese patients with hepatitis C virus infection. *Clin Cancer Res*, 2004; 10:2441-6. *Clin Cancer Res*, 2005;11:1348-9.
  4. **Innocenti F**, Ratain MJ. Correspondence re: Raida M. *et al.*, Prevalence of a common point mutation in the *dihydropyrimidine dehydrogenase (DPD)* gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls, published on *Clin Cancer Res*, 2001;7:2832-9. *Clin Cancer Res*, 2002;8:1314-6.

### Conference Reports

1. Koromina M, Konstantinidou V, Georgaka M, **Innocenti F**, Patrinos GP. Nutrigenetics and Nutrigenomics: Ready for clinical use or still a way to go? *Pers Med (in press)*
2. Visvikis-Siest S, Gorenjak V, Stathopoulou MG, Petrelis AM, Weryha G, Masson C, Hiegel B, Kumar S, Barouki R, Boerwinkle E, Dagher G, Deloukas P, **Innocenti F**, Lamont J, Marschler M, Meyer H, Meyer UA, Nofziger C, Paulmichl M, Vacher C, Webster L. The 9<sup>th</sup> Santorini Conference: Systems Medicine, Personalized Health and Therapy. “The Odyssey from Hope to Practice”, Santorini, Greece, 30 September-3 October 2018. *J Pers Med*. 2018 Dec 12;8(4). PMID 30545130.
3. Patrinos PG, **Innocenti F**. Conference scene. Pharmacogenomics: paving the path to personalized medicine. Golden Helix Symposium. Athens, Greece, 15-17 October 2009. *Pharmacogenomics*, 2010; 11:141-6.
4. Patrinos GP, **Innocenti F**, Cox N, Fortina P. Genetic Analysis in Translational Medicine: The 2010 Golden Helix Symposium. *Hum Mutat*, 2011; 32:698. PubMed Central PMCID: PMC 3795430.
5. Fortina P, Khaja N, Ali M, Hamzeh A, Nair P, **Innocenti F**, Patrinos G, Kricka L. Genomics into healthcare: the 5th Pan Arab Human Genetics Conference and 2013 Golden Helix Symposium. *Hum Mutat*, 2014;35:637-40. PubMed Central PMCID: PMC 4128335.

### Book Reviews

1. **Innocenti F**. Pharmacogenetics and individualized therapy. *Clin Pharmacol Ther*, 2012;92:682.
2. **Innocenti F**. Polypharmacology in drug discovery. *Clin Pharmacol Ther*, 2012;92:279-80.

### TEACHING RECORD

#### University of North Carolina at Chapel Hill

#### **2019 PHCY 837 - Pharmacogenomics**

Case study: DPD deficiency and 5-FU-related severe toxicity, 6 h

Methodology of clinical trials in pharmacogenomics, 6 h

#### Course Director - 2018 DPET 873 - Precision Therapy Through Genomics

The clinical need for individualized therapy, 1.5 h

Trial design for pharmacogenomics studies/genome-wide association studies, 1.5 h

Applying cancer genome mutations to individualize therapy, 3 h

Case study: DPD deficiency and 5-FU-related severe toxicity, 3 h

**Course Director - 2018 PHRS 899 - DPET Seminar in Pharmaceutical Sciences**

**2018 PHCY 837 - Pharmacogenomics**

Case study: DPD deficiency and 5-FU-related severe toxicity, 6 h

Methodology of clinical trials in pharmacogenomics, 6 h

**2017 PHCY 837 - Pharmacogenomics**

Case study: DPD deficiency and 5-FU-related severe toxicity, 6 h

Methodology of clinical trials in pharmacogenomics, 6 h

**Course Director - 2017 PHRS 899 - DPET Seminar in Pharmaceutical Sciences**

**Course Director - 2016 PHRS 899 - DPET Seminar in Pharmaceutical Sciences**

**Course Director - 2016 DPET 832 - Introduction to Applied Pharmacogenomics**

The clinical need for individualized therapy, 2 h

Trial design for pharmacogenomics studies/genome-wide association studies, 2 h

Group activities, 2 h

Applying cancer genome mutations to individualize therapy, 2 h

**2015 MOPH 810 - Drug Metabolism**

Pharmacogenetics of drug metabolism in cancer therapy, 2 h

**Course Director - 2015 DPET 832 - Introduction to Applied Pharmacogenomics**

The clinical need for individualized therapy, 2 h

Trial design for pharmacogenomics studies/genome-wide association studies, 2 h

Group activities, 2 h

Applying cancer genome mutations to individualize therapy, 2 h

**2015 DPET 8383 - Methods in Pharmacogenomics**

Cancer Pharmacogenomics, 2 h

**Course Director - 2014 DPET 832 - Introduction to Applied Pharmacogenomics**

The clinical need for individualized therapy, 2 h

Trial design for pharmacogenomics studies/genome-wide association studies, 2 h

Group activities, 2 h

Applying cancer genome mutations to individualize therapy, 2 h

**2014 MOPH 810 - Drug Metabolism**

Pharmacogenetics of drug metabolism in cancer therapy, 2 h

**Course Director - 2013 DPET 832 - Introduction to Applied Pharmacogenomics**

Trial design for pharmacogenomics studies, 1.5 h

Group activities, 3 h

2013 *DPET 838 - Methods in Pharmacogenomics*

A case study of pharmacogenomics, 1.5 h

2011 *DPET 832 - Introduction to Applied Pharmacogenomics, Fall Semester*

Haplotypes, QTLs and the chromosome, and candidate gene discovery with microarrays, 1 h

2011 *School of Pharmacy, Honor Students, Fall Semester*

Translational research program in cancer pharmacology, 1.5 h

**University of Chicago**

**Course Director - Pritzker School of Medicine, Pharmacology Course (2004 - 2010)**

*Classes and lecture time*

2010, 6 h; Pharmacodynamics, Immunopharmacology, Anti-inflammatory drugs, Variability in drug response.

2009, 10 h; Pharmacokinetics, Pharmacodynamics, Immunopharmacology, Anti-inflammatory drugs, Toxicology, Variability in drug response, Course reviews.

2008, 10 h; Pharmacokinetics, Pharmacodynamics, Immunopharmacology, Anti-inflammatory drugs, Toxicology, Variability in drug response, Course reviews.

2007, 10 h; Pharmacokinetics, Pharmacodynamics, Immunopharmacology, Anti-inflammatory drugs, Toxicology, Variability in drug response, Course reviews.

2006, 9 h; Principles of pharmacokinetics, Principles of pharmacodynamics, Principles of pharmacogenetics, Anti-cancer drugs, Principles of toxicology, Course reviews.

2005, 9 h; Principles of pharmacokinetics, Principles of pharmacodynamics, Anti-inflammatory pharmacology, Immunopharmacology, Variability in drug response, Course reviews.

2004, 10.5 h; Principles of pharmacokinetics, Principles of pharmacodynamics, Principles of pharmacogenetics, Principles of toxicology, Principles of drug-drug interactions, Chemotherapy, Course reviews.

**Other Teaching Activities: Lectures, Classes, Seminars**

2019 *UNC at Chapel Hill, T32 Seminar - Clinical Pharmacology Postdoctoral Training Program. Precision Medicine and Methodological Attention, 1.5 h*

Faculty Mentor, T32 Clinical Pharmacology Training Grant, PI Dr. Brouwer (2015 - present)

2015 *UNC at Chapel Hill, T32 Seminar - Clinical Pharmacology Postdoctoral Training Program. Rare phenotypes in cancer therapy, 1.5 h*

2014 *Duke University, PHAR370S - Pharmacogenomics and Personalized Medicine*  
Pharmacogenics in cancer therapy, 2 h

2008 University of Chicago, *Hematology/Oncology Core Curriculum Lecture Series 2008*.  
Pharmacokinetics and Pharmacodynamics, 1 h

2008 University of Chicago, *Undergraduate Pharmacology Course*. Drug Metabolism, 1 h

2007 University of Chicago, *Undergraduate Pharmacology Course*. Drug metabolism, 1 h

2007 University of Chicago, *Hematology/Oncology Core Curriculum Lecture Series 2007*.  
Pharmacokinetics and Pharmacodynamics, 1 h

2006 University of Chicago, *Undergraduate Pharmacology Course*. Drug Metabolism, 1 h

2004 University of Chicago, *Course on Multidisciplinary Approaches to Psychiatric and Behavioral Genetics*. Pharmacogenetics. Department of Psychiatry, 1.5 h

2004 University of Chicago, *Frontiers in Cancer Research: Exploiting Molecular Targets in Cancer Therapy*. Pharmacogenetics of phase II enzymes. Biological Sciences Learning Center, 1 h

2003 University of Chicago, *Hematology/Oncology Core Curriculum Lecture Series 2003*. Pharmacokinetics and Pharmacodynamics, 1 h

## **Mentoring of Trainees**

### Current Trainees

*Emily Shen* - Undergraduate Biology student at UNC at Chapel Hill (February 2020 - present)

*Evangelia Termpini, PharmD* - Visiting post-doctoral student from the School of Pharmacy in Patras, Greece (October 2019 - present)

*Julia Quintanilha, PharmD* - Visiting PhD student from Campinas University, Sao Paulo, Brazil (January 2019 - present)

*Spinel Karas, PharmD* - PhD student in Pharmaceutical Sciences (Main Advisor, August 2018 - present)

*Sarah Mills* - 3<sup>rd</sup> year Pharmacy student at the UNC School of Pharmacy (October 2017 - present)

*Alessandro Racioppi* - UNC Post-Baccalaureate Pre-Health Program (July 2017 - present)

### Past Trainees

*Kevin Huang* - Undergraduate student (June 2019 - September 2019)

*Allison Karabinos* - An honors student at the UNC School of Pharmacy (April 2014 - January 2017)

*Erin Conner* - An undergraduate Chemistry student at UNC (October 2013 - May 2016)

*Evonne McArthur* - An undergraduate Quantitative Biology student at UNC (January 2014 - June 2015)

*Daniel Crona, PharmD* - A PhD student in Pharmaceutical Sciences at UNC School of Pharmacy (Main Advisor, January 2011 - September 2015)

*Eric Seiser, PhD* - A Post-Doctoral Scholar (May 2013 - May 2015)

*Timaeus Sarah* - An honors student at the UNC School of Pharmacy (June 2012 - 2015)

*Gillis Nancy, PharmD* - A PhD student in Pharmaceutical Sciences at the UNC School of Pharmacy (August 2012 - October 2014)

*Cathy Chang, PharmD* - A PhD student in Pharmaceutical Sciences at the UNC School of Pharmacy (August 2013 - August 2014)

*Danielle Schlafer* - An honors student at the UNC School of Pharmacy (February 2012 - August 2013)

*Dylan Glubb, PhD* - A Post-Doctoral Scholar (January 2009 - February 2013)

*Keith, Schmidt* - An honors student at the UNC School of Pharmacy (March 2012 - December 2012)

*Neepa Dholakia, PharmD* - A PhD student in Pharmaceutical Sciences at the UNC School of Pharmacy (July 2012 - October 2012).

*Zheng Hu, PhD* - A Post-Doctoral Scholar (January 2011 - July 2012)

### **Student Advisory Committees**

*Jin Wang* (graduated 2019 - Mentor Dr. Danyu Lin, UNC Department of Biostatistics)

*Daniel Gonzalez* (PhD student - Mentor Dr. Tim Wiltshire, UNC Eshelman School of Pharmacy)

### **Co-mentored Trainees/Mentees and Mentorship in Training Grants**

*Sharma Manish R, MD; Nagasubramanian Richard, MD; Desai Apurva, MD; Undevia Samir, MD; Kim Tae Won, MD; Yong Wei Peng, MD; Evans Patrick, PhD; Mirkov Snezana, MS; Ramirez Jacqueline, MS; Etheridge Amy, MS; Stefanie Dennings; Kelli Hammond; Michael Lee, MD; Liu Wanqing, PhD; Asher Gary, MD (Advisory Board Member on his K23 application); Academic Training in Oncology at the University of North Carolina at Chapel Hill (5T32CA128590-04, PI Dr. Lisa Carey)*

## **GRANTS**

### **Ongoing Funding**

Alliance for Clinical Trials in Oncology Foundation. Sorafenib pharmacogenomics in CALGB 80802 study. **Innocenti F (PI)** (1/28/2019 - 1/27/2021)

UNC Eshelman Institute for Innovation. Defining the microbiome in colorectal cancer to achieve precision therapeutics. **Innocenti F (PI)** (7/1/2018 - 6/30/2020)

Alliance for Clinical Trials in Oncology Foundation. Translation of genomic data into biomarkers in patients enrolled in CALGB/SWOG C80405 study. **Innocenti F (PI)** (4/1/2015 - 3/31/2020)

Alliance for Clinical Trials in Oncology Foundation. Analysis of biospecimens from the CALGB/SWOG C80405 study. **Innocenti F (PI)** (3/1/2015 - 3/31/2020)

NIH/NCI/2P01 CA142538-06. Statistical methods for cancer clinical trials. Kosorok M (PI). **Innocenti F (Co-I)** (04/01/20 - 03/31/25)

### **Pending Funding**

NIH/NCI/R01 CA244495-01. Discovery and functional analysis of mutations that affect immune evasion and patient survival in metastatic colorectal cancer. **Innocenti F (PI)**

Alliance for Clinical Trials in Oncology Foundation Special Projects Allocation. Individualized treatment rules for therapy selection in the treatment of metastatic colorectal cancer. **Innocenti F (PI)**

UNC Lineberger Comprehensive Cancer Center, Stimulus Award. Machine learning-based selection of optimized therapy in cancer patients. **Innocenti F (Co-PI)**

NIH/NCI/R01 SA-PAR-18-654. Identification of the genetic basis of health disparity in African American men with prostate cancer through transcriptional analysis. **Innocenti F** (Subcontract PI), Owzar PI

NIH/NHLBI/R01 NOT-HL-19-676. Identifying metabolomics causal networks and pathways in cardiovascular disease using genetics. **Innocenti F (Co-I)**, Yazdani PI



## Past Funding

- NIH/2R01 GM047845-25. Semiparametric analysis of censored data in current medical studies. Lin D (PI). **Innocenti F** (Co-I) (8/15/2015 - 5/31/2019) - 5% salary recovery
- NIH/NCI/UM1 CA186704-02. Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis (ET-CTN). Dees C, Hurwitz H (Co-PIs). **Innocenti F** (Co-I) (3/1/2017 - 2/28/2018) - 5% salary recovery
- NIH/1R21 CA178550-02. A new model for discovering genetic determinants of angiogenesis and the effect of VEGF-pathway inhibitors. **Innocenti F (PI)** (4/7/14 - 3/21/16) \$275,000
- NIH/NICHD/1R01HD085512-01. A systems approach to pediatric Pediatrics. Liu W, Li L, Renbarger J (PIs). **Innocenti F** (Co-I)
- University Cancer Research Fund, Innovation Awards. A phase II UGT1A1 genotype-guided study of irinotecan in metastatic colorectal cancer patients receiving FOLFIRI + bevacizumab. **Innocenti F (PI)** (8/1/13 - 6/30/15) \$180,000
- Triad Golfers Against Cancer Foundation. A clinical trial to personalize dosing of chemotherapy in metastatic colorectal cancer patients. **Innocenti F (PI)** (2/1/14 - 1/31/15) \$65,000
- Alliance for Clinical Trials in Oncology Foundation - Activity as a Chairman of Correlative Science of the Gastrointestinal Solid Tumor Committee. **Innocenti F (PI)** (9/1/13 - 8/31/14) \$15,000
- Alliance for Clinical Trials in Oncology Foundation - Pharmacogenetic studies of angiogenesis in advanced pancreatic cancer patients. **Innocenti F (PI)** (7/1/13 - 6/30/14) \$168,000
- NIH/NCI K07CA140390-01 - Genome-wide molecular epidemiology of treatment outcome and cancer risk. **Innocenti F (PI)** (9/23/09 - 8/31/14) \$1,030,695
- NIH/NIGMS U01GM61393-11 - Pharmacogenetics of Anticancer Agents Research Group. Ratain/Dolan/Cox (Project PIs). **Innocenti F** (Co-I) (7/1/10 - 6/30/15) \$1,426,916
- Alliance for Clinical Trials in Oncology Foundation - Activity as a Chairman of Correlative Science of the Gastrointestinal Solid Tumor Committee. **Innocenti F (PI)** (9/1/12 - 8/31/13) \$15,000
- NIH/NIDDK R21DK081157-01A2 - Genome-wide SNP genotyping and gene expression analysis in human livers. **Innocenti F (PI)** (5/1/09 - 4/30/13) \$238,984
- NIH/NCI U01 CA69852 - Phase I clinical trials of anti-cancer agents. Ratain MJ (Project PI). **Innocenti F** (Co-I) (3/1/02 - 2/29/13) \$524,375
- NIH/NCI R21CA139280-01 - A comprehensive pharmacogenetic study of sorafenib in renal cell carcinoma patients. **Innocenti F (PI)** (3/1/09 - 1/31/12) \$161,021
- American Cancer Society, Illinois Division - Molecular signatures of angiogenesis in NSCLC and their prognostic role. **Innocenti F (PI)** (2/1/10 - 1/31/11) \$100,000
- NIH/NIGMS U01 GM61393-10 - Pharmacogenetics of Anticancer Agents Research Group. Ratain MJ (PI). **Innocenti F** (Co-I) (6/1/01 - 6/30/10) \$2,192,727
- Wendy Will Case Cancer Fund - Gene expression variation in angiogenesis genes in lung cancer and its prognostic significance. **Innocenti F (PI)** (1/1/09 - 12/31/09) \$15,000
- Joan's Legacy - VEGFR-2 genetic variation in bronchioalveolar carcinoma. **Innocenti F (PI)** (1/1/08 - 12/31/09) \$50,000
- NIH/NCI R21 "Busulfan conditioning: optimization, kinetics, genomics" van Besien K (PI). **Innocenti F** (Co-I) (12/1/05 - 4/30/09) \$193,120

University of Chicago Cancer Research Center - Pilot funding opportunity in the area of genome-wide association studies (GWA) of cancer risk and/or prognosis. Genome-wide SNP genotyping and gene expression analysis in human livers. **Innocenti F (PI)** (11/1/07 - 10/31/08) \$40,000

Abbott Laboratories “Pharmacogenetic sub-study to protocol M01-303 (A Phase I escalating multiple dose study with continuous dosing of ABT-751 in patients with advanced cancer)”. **Innocenti F (PI)** (7/1/05 - 6/30/06) \$150,000

NIH/R21 CA101323 NIH/Hopkins Subcontract - A pharmacogenetic and pharmacodynamic study of erlotinib. Desai A (PI). **Innocenti F (Co-I)** (5/1/04 - 4/30/06) \$144,176

Cancer Research Center, University of Chicago, Protocol-Specific Research - A phase 1 genotype-directed dose-escalation study of irinotecan (NSC616348, CPT-11, Camptosar®) in patients with advanced solid tumors. **Innocenti F (PI)** (8/1/05 - 3/31/06) \$25,000

NIH/P30 CA14599-27S1. NIH/NCI/NCCAM - Modulation of irinotecan metabolism and disposition by green tea and soy extracts. **Innocenti F (PI)** (9/1/01 - 8/30/02) \$212,000

### **Reviewer in Study Sections**

NIH-NCI, Participant Engagement and Cancer Genome Sequencing Centers SEP, USA, 2020

NIH-NIGMS (not accepted due to conflict with the one above), Limited Competition: NIGMS National and Regional Resources (R24 - Clinical Trial Not Allowed), USA, 2020

University of Florida - Bankhead-Coley Cancer Research Program, USA, 2019

LCCC Internal evaluation of K99/F00 candidates, Chapel Hill, NC, 2019

Fonds National de la Recherche Luxembourg, Luxembourg, 2019

National Clinical Trial Network, Core Correlative Sciences Committee-B, Primary reviewer of two proposals, USA, 2019

ZCA1 RPRB-6(O2) NCI Clinical and Translational R21 and Omnibus R03– SEP-1, USA, 2019

Kuwait Foundation for the Advancement of Sciences, Kuwait, 2019

National Science Center, Poland, 2018

Pharmacogenetics Research Network - Riken, USA, 2017

Health Research Board, Dublin, Ireland, 2017

University of Florida - Bankhead-Coley Cancer Research Program, USA, 2016

International Committee for the Clinical Research in Cancer - Paris, France, 2016

Pharmacogenetics Research Network (PGRN) - Riken, USA, 2016

University of Florida - Bankhead-Coley Cancer Research Program, USA, 2015

University of Florida - Bankhead-Coley Cancer Research Program, USA, 2015

Sardegna Ricerche, Cagliari, Italy, 2015

UNC Lineberger Developmental Awards, 2015

University of Florida - James and Esther King Biomedical Research Program, USA, 2015

National Institute of Health - National Institute of General Medical Sciences - P50s, USA, 2015

Ministry of Health of the Czech Republic, Czech Republic, 2015

Science Foundation Ireland, Ireland, 2014

University Cancer Research Funds Innovation Awards, USA, 2014

Pennsylvania Department of Health Final Performance Review, USA, 2013

Compagnia di San Paolo, Area Sanità e Ricerca Scientifica, Italy, 2013

National Science Center, Poland, 2013

Pennsylvania Department of Health Final Performance Review, USA, 2012

LUNGeVity Foundation, USA, 2012

Sardegna Ricerche, Cagliari, Italy, 2012

National Institute of Health - National Human Genome Research Institute, Administrative Supplement Program, USA, 2012

Compagnia di San Paolo, Area Sanità e Ricerca Scientifica, Italy, 2012

National Institute of Health - National Institute of Diabetes and Digestive and Kidney Diseases - R01s, USA, 2011

Italian Health Ministry, Italy, 2010

Bankhead-Coley Cancer Research Program managed by the Florida Department of Health, USA, 2010

Foundation Fournier - Majoie pour l'Innovation (FFMI), France, 2009

National Institute of Health, Challenge Grants, USA, 2009

University of Chicago - Argonne Seed Grant, USA, 2007

National Medical Research Council, Singapore, 2007

Istituto Toscano Tumori, Italy, 2007

Foundation Fournier - Majoie pour l'Innovation (FFMI), France, 2007

NHS Blood and Transplant, R&D funds, United Kingdom, 2006

Institut National Du Cancer, France, 2005

Dutch Cancer Society, The Netherlands, 2004

## **PROFESSIONAL SERVICE**

### **Membership of Professional Societies**

American Association of Colleges of Pharmacy (2012 - present)

European Society of Pharmacogenomics and Theranostics (2011 - present)

Golden Helix® Institute of Biomedical Research, Board Member (2009 - present)

National Lung Cancer Partnership (2007 - present)

American Association for Cancer Research (2005 - present)

Cancer and Leukemia Group B (2003 - present)

Pharmacogenetics Research Network (2002 - present)

American Society of Clinical Oncology (2001 - present)

American Society of Clinical Pharmacology and Therapeutics (2000 - present)

## Patent Applications

United States Provisional Application "Methods of identifying risk of bevacizumab-induced proteinuria and hypertension", **Innocenti F**, Quintanilha J, Lin D, Owzar K, Wang J. Filed on September 20, 2019, serial number 62/903,442.

United States Patent: "Optimization of cancer treatment with irinotecan", Ratain MJ, **Innocenti F**, Karabatsos P, Grimsley C, Di Rienzo A. Filed on February 12, 2003, serial number 60/446,942.

United States Patent: "Flavopiridol drug combinations and methods with reduced side effects", Ratain MJ, **Innocenti F**, Iyer L. Filed on April 12, 2001, serial number 09/835,082.

## Invited Reviewer for Scientific Journals

Annals of Oncology, American Journal of Cancer, American Journal of Health-System Pharmacy, American Journal of Hematology, American Journal of Managed Care, BioMed Central Cancer, BioMed Central Medical Genetics, BioMed Central Medical Genomics, British Journal of Cancer, British Journal of Clinical Pharmacology, Cancer, Cancer Chemotherapy and Pharmacology, Cancer Research, Cancer Science, Chemotherapy, Clinical Cancer Research, Clinical Chemistry, Clinical Colorectal Cancer, Clinical Pharmacology and Therapeutics, Clinical Pharmacokinetics, Community Oncology, Current Drug Metabolism, Current Opinion in Molecular Therapeutics, Current Pharmacogenomics, Drug Metabolism and Disposition, European Journal of Cancer, Expert Opinion on Drug Safety, Expert Opinion on Drug Metabolism and Toxicology, Expert Opinion on Pharmacotherapy, Expert Review of Anticancer Therapy, Expert Review of Molecular Diagnostics, Genetic Epidemiology, Genetics in Medicine, Genome Medicine, Human Mutation, International Journal of Cancer, International Journal of Medical Sciences, Journal of Cellular and Molecular Medicine, Journal of Clinical Oncology, Journal of Clinical Pharmacology, Journal of the National Cancer Institute, Leukemia and Lymphoma, Molecular Pharmacology, Nature, Nature Communications, Nature Reviews in Clinical Oncology, Oncotarget, Personalized Medicine, Pharmacogenetics, Pharmacogenetics and Genomics, Pharmacogenomics, PLoS One, Scientific Reports, Systems Biology in Reproductive Medicine, The Oncologist, The Pharmacogenomics Journal, Therapeutic Drug Monitoring, Trends in Pharmacological Sciences, Vascular Cell.

## Oral Presentations at International Conferences (Selected by Competition)

1. **Innocenti F**, Rashid N, Wancen M, Ou FS, Qu X, Denning S, Bertagnolli M, Blanke CD, Venook AP, Kabbarah O, Lenz HL. Next-generation sequencing (NGS) in metastatic colorectal cancer (mCRC): novel mutated genes and their effect on response to therapy. *European Society for Medical Oncology - Annual Meeting*, 2019.
2. **Innocenti F**, Ou FS, Zemla T, Niedzwiecki D, Qu X, Tam R, Mahajan S, Goldberg R, Mayer R, Bertagnolli M, Sanoff H, Hochster HS, Blanke CD, Venook AP, Lenz HL, Kabbarah O. Somatic DNA mutations, MSI status, mutational load (ML): association with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance). *American Society of Clinical Oncology - Annual Meeting*, 2017.
3. **Innocenti F**, Owzar K, Jiang C, Sibley AB, Niedzwiecki D, Bertagnolli MM, Friedman PN, Furukawa Y, Kubo M, Ratain MJ, Blanke CD, Lenz H-J, Venook AP, McLeod HL. A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405. *European Society for Medical Oncology Annual Meeting*, 2015.

4. **Innocenti F**, Pare<sup>2</sup>-Brunet L, Jantus-Lewintre E, Rzyman W, Jassem J, Hirsch RF, Owzar K, Camps C, Dzadziuszko R, Glubb MD. FLT1 gene variation as a major determinant of recurrence in stage I-III non-small cell lung cancer. *European Society for Medical Oncology Annual Meeting*, 2013.
5. **Innocenti F**, Leon I. Goldberg Young Investigator Award. A pharmacogenomics imperative: “Get the phenotype right!”. *American Society for Clinical Pharmacology and Therapeutics - Annual Meeting*, 2013.
6. **Innocenti F**, Owzar K, Glubb D, Jiang C, Hu Z, Etheridge A, Cox NJ, Kubo M, Mushiroda T, Kindler HL, Venook AP, McLeod HL, Nakamura Y, Ratain MJ, Bamlet WR, McWilliams RR. Role of vitamin D receptor (VDR) gene polymorphisms for overall survival in pancreatic cancer: genome-wide association and functional mechanistic studies. *AACR Special Conference on Pancreatic Cancer: Progress and Challenges*, 2012.
7. **Innocenti F**, Glubb DM, Zhang W, Owzar K, Jiang C, Mirza O, Kashyap S, Rzyman W, Jassem J, Hirsch FR, Dziadziuszko R. Germline genetic variants in the vascular endothelial growth factor (VEGF) pathway and survival in non-small cell lung cancer. *NCI Translational Science Meeting*, 2011.
8. **Innocenti F**, Ramírez J, Xiong J, Chiu Y, Katz DA, Carr R, Zhang W, Das S, Adjei A, Moyer A, Chen PX, Krivoshik A, Medina D, Gordon GB, Ratain MJ, Fleming G, Sahelijo L, Weinshilboum RM, Bhatena A. Combining *in vitro* metabolism data and clinical pharmacology for understanding pharmacokinetic variability and pharmacogenetic associations. The example of the novel anticancer agent ABT-751. *American Society for Clinical Pharmacology and Therapeutics - Annual Meeting*, 2010.
9. **Innocenti F**, Kroetz DL, Schuetz E, Dolan ME, Ramirez J, Relling M, Chen P, Das S, Rosner GL, Ratain MJ. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. *American Society for Clinical Pharmacology and Therapeutics - Annual Meeting*, 2009.
10. **Innocenti F**, Janisch L, Das S, Ramirez J, House L, Maitland ML, Salgia R, Ratain MJ. A genotype-directed phase I study of irinotecan in advanced cancer patients. *American Society of Clinical Oncology - Annual Meeting*, 2007.
11. **Innocenti F**, Undevia SD, Rosner GL, Xiao L, Liu W, Chen P, Das S, Ramirez J, Kroetz DL, Ratain MJ. Irinotecan (CPT-11) pharmacokinetics (PK) and neutropenia: interaction among UGT1A1 and transporter genes. *American Society of Clinical Oncology - Annual Meeting*, 2005.
12. **Innocenti F**, Undevia SD, Chen PX, Das S, Ramirez J, Dolan ME, Relling MV, Kroetz DL, Ratain MJ. Pharmacogenetic analysis of interindividual irinotecan (CPT-11) pharmacokinetic (PK) variability: evidence for a functional variant of ABCC2. *American Society of Clinical Oncology - Annual Meeting*, 2004.
13. **Innocenti F**, Undevia SD, Iyer L, Das S, Karrison T, Janisch L, Ramirez J, Rudin CM, Vokes EE, Ratain MJ. *UGT1A1*\*28 polymorphism is a predictor of neutropenia in irinotecan chemotherapy. *American Society of Clinical Oncology - Annual Meeting*, 2003.
14. **Innocenti F**, Iyer L, Ramírez J, Green MD, Ratain MJ. Investigation of genetic variations in epirubicin metabolism. *Molecular Biology and Pharmacogenetic Research in the Treatment of Lung Cancer. Barcelona, Spain*, 2001.
15. **Innocenti F**, Iyer L, Ramirez J, Green MD, Ratain MJ. Pharmacogenetic studies on epirubicin metabolism. *European Organization for Research and Treatment of Cancer. Verona, Italy*, 2001.

16. **Innocenti F**, Stadler WM, Iyer L, Vokes EE, Ratain MJ. Flavopiridol-induced diarrhea is related to systemic metabolism of flavopiridol to its glucuronide. *American Society of Clinical Oncology - Annual Meeting*, 2000.
17. **Innocenti F**, Danesi R, Nardini D, Barachini S, Favre C, Vezzani S, Macchia P, Del Tacca M. Relationship between cellular 6-thioguanine metabolites, cytotoxicity in vitro and myelotoxicity in patients. *6<sup>th</sup> Joint Meeting of the Italian, Hungarian and Polish Pharmacological Societies*, 1998.

## Invited Speaker

### 2020

*The 10<sup>th</sup> Santorini Conference. Systems Medicine and Personalized Health and Therapy. The Odyssey from Hope to Practice: Patient First.* The immune system and its interaction with the tumor genome: patient survival and response. 2020, Santorini, Greece.

*The 3<sup>rd</sup> Zayed Center Genomic Medicine Conference & 23<sup>rd</sup> Golden Helix Pharmacogenomics Day. College of Medicine and Health Sciences, UAE University.* Novel determinants of safety and efficacy of cancer therapy. Al-Ain, United Arab Emirates.

### 2019

*University of Athens, 6<sup>th</sup> U-PGx Personalized Medicine Day.* Application of genetics and genomics to improve the efficacy and safety of anticancer treatments. Athens, Greece.

*University of Athens.* Clinical Trial Networks for Cancer Drug Development and the Opportunity They Offer. Athens, Greece.

*University of Campinas.* Pharmacogenetic variability in drug response. Campinas, Brazil.

*Center Antoine Lacassagne.* Genomics applications in oncology. Nice, France.

*University of Arizona, School of Pharmacy.* Application of genetics and genomics to improve the efficacy and safety of anticancer treatments. Tucson, AZ, USA.

*University of Patras, School of Pharmacy.* Precision medicine and methodological attention. Patras, Greece.

*University of Tor Vergata, Department of Medicine. 2nd Ubiquitous Pharmacogenomics Personalised Medicine Public Day.* Genomics applied to cancer therapy. Rome, Italy.

### 2018

*The 9<sup>th</sup> Santorini Conference. Systems Medicine and Personalized Health and Therapy.* Safety of cancer treatment: a genomic perspective. 2018, Santorini, Greece.

*University at Buffalo, The State University of New York, School of Pharmacy and Pharmaceutical Sciences. Fall Seminar Series.* Genomics for Precision Therapeutics in Oncology. Buffalo, NY.

*2018 Golden Helix Summer School: Rare genomics: genomics of rare diseases, rare cancer, and rare drug outcomes.* Safety of cancer treatment. 2018, Syros Island, Greece.

*39<sup>th</sup> EORTC-PAMM Winter meeting.* Genomic strategies leading to improved outcome in colorectal cancer patients. Rome, Italy.

*Duke Genomic & Precision Medicine Forum.* On 6/12/2017, Precision Oncology is still of relevance. Duke University, Durham, NC.

### 2017

*University of Southern California. School of Pharmacy.* Application of genomics to improve the efficacy and safety of anticancer treatments. Los Angeles, CA.

*Pharmacogenomics Research Network - RIKEN Center for Integrative Medical Sciences (IMS) Strategic Alliance Meeting.* Ongoing and planned studies in colorectal cancer patients: Update on CALGB 80405. San Francisco, CA.

*Regeneron.* Mechanistic inference of clinical genetic data of drug response in oncology. Terrytown, NY.

*Genentech.* Genomic tools for personalized oncology. South San Francisco, CA.

*Global Genomic Medicine Collaborative Meeting: Implementing Genomic Medicine Globally.* Genomic medicine, safety first. Athens, Greece.

*2nd UPGx Personalized Medicine Day.* A lot of discovery and little application of genetic markers of drug response in oncology. Vienna, Austria.

## 2016

*Joint Lake Nona-Roche Meeting.* Genomic tools for safer drugs in oncology. Lake Nona, FL.

*Antoine Lacassagne Cancer Center, Scientific Council.* Phase I trials and translational studies in oncology. Nice, France.

*Alliance for Clinical Trials in Oncology Spring Group Meeting; Pharmacogenomics and Population Pharmacology Committee.* 80405: Genome-wide association study of survival in metastatic colorectal cancer. Chicago, IL.

*Alliance for Clinical Trials in Oncology Fall Group Meeting; Pharmacogenomics and Population Pharmacology Committee.* 80405: Update on genome-wide association studies. Chicago, IL.

*UNC Cancer Network. Pharmacogenomics and Individual Therapy Research.* Chapel Hill, NC.

*2016 Duke-Industry Statistical Symposium. Precision Medicine in Cancer Research.* Cancer treatment and use of germline genetics for determining precision in drug therapy. Durham, NC.

*University of California at San Francisco.* Use of genetics to individualize drug therapy in cancer patients. San Francisco, CA.

*8<sup>th</sup> Santorini Conference. Systems Medicine, Personalized Health and Therapy.* Genomic precision to be achieved in the use of VEGF-inhibitors in cancer patients. Santorini, Greece.

## 2015

*Antoine Lacassagne Cancer Centre.* Efforts towards increasing precision in the drug treatment of cancer patients. Nice, France.

*Karolinska Institute.* Genetics to achieve precision in cancer therapy. Stockholm, Sweden.

*Alliance for Clinical Trials in Oncology Fall Group Meeting; Pharmacogenomics and Population Pharmacology Committee.* 80405: Genome-wide association study of survival in metastatic colorectal cancer. Chicago, IL.

*Pharmacogenomics Research Network - RIKEN Center for Integrative Medical Sciences (IMS) Strategic Alliance Meeting*. Genetic basis of variability in VEGF plasma levels. Yokohama, Japan.

*14th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology*. What evidence do we need to implement pharmacogenetics? Rotterdam, The Netherlands.

*American Society of Clinical Oncology 2015 Annual Meeting. Meet the Professor Session: Achieving Precision Medicine through Therapeutic Drug Monitoring and Pharmacogenomics*. Pharmacogenomics to Predict Cancer Outcomes and Responses to Anti-Cancer Therapies. Chicago, IL.

## 2014

*Alliance for Clinical Trials in Oncology Fall Group Meeting; Translational Research Program Symposium. Interdisciplinary Efforts To Increase The Translational Potential Of Neoadjuvant Trials*. Strategies for meaningful biomarkers in neoadjuvant trials. Chicago, IL.

*Golden Helix Symposium 2014: Genomics of Rare Diseases*. Keynote talk. Exceptional responders in cancer therapy. Belgrade, Serbia.

*Pharmacogenetics Research Network-RIKEN Strategic Alliance Meeting*. Update on CALGB 80303. Yokohama, Japan.

*Plenary Session, Alliance for Clinical Trials in Oncology, Spring Group Meeting*, Clinical research challenges in tumor genomics analysis. Chicago, IL.

*Pharmacogenetic Research Network/Riken/Center for Genomic Medicine Meeting*. Colorectal cancer pharmacogenomics (phase II). San Francisco, CA.

## 2013

*ASCPT Annual Meeting*. Cancer genome: current status and opportunities. Indianapolis, IN.

*Bio-IT World Conference 2013*. The challenges integrating information during the discovery of biomarkers in cancer patients treated with chemotherapy: A pharmacology and oncology perspective. Boston, MA.

*University of Chicago: Pharmacogenetic of Anticancer Agent Research Group, Seminar series*. Pharmacogenetics of VEGF-pathway inhibitors. Chicago, IL.

*Keystone Symposium: Human Genomics and Personalized Medicine*. Pharmacogenetics of cancer therapeutics: focus on the germline genome. Stockholm, Sweden.

*European Society of Pharmacogenomics and Theranostics, Second Conference: Pharmacogenomics: from Cell to Clinic*. Improving cancer drug therapy through the patient genomes. Lisbon, Portugal.

*University of Sydney*. From cancer genome sequencing to germline pharmacogenetics – a step closer to improved therapies? Sydney, Australia.

*University of Florida*. Understanding the process for achieving the evidence for clinical utility of germline genetic markers in oncology. Gainesville, FL.

*Golden Helix Pharmacogenomics Day, National Cancer Center*. Personalizing therapy in cancer patients. Aviano, Italy.

## 2012

*Meeting on Current Strategies in the Treatment of Colorectal and Non-Colorectal Gastrointestinal Cancers - State of the Art Lecture*. Germline variations as predictive markers in gastrointestinal malignancies. Los Angeles, CA.



*Winship Cancer Institute, Emory University, Grand Rounds. Genomics, “good drugs...bad drugs... “. Atlanta, GA.*

*Golden Helix Symposium 2012. Is there a role for heritable genomics in determining the outcome of chemotherapy?. Turin, Italy.*

*Distinguished Lecture in Human Resource Development Plan for Cancer 2012 at Kobe University. Ways to use genetic and genomic information to improve safety and efficacy of anticancer drugs. Kobe, Japan.*

*European Medicines Agency: Pharmacogenomic Network Expert meeting and informal CHMP Pharmacogenomics Working Party (PGWP). Applying genomic strategies to improve drug therapy: a rapidly evolving field. Salzburg, Austria.*

*University of Cambridge, Cambridge Oncology Seminar Series. A genomic Odyssey of predicting drug response: is Ulysses home yet?. Cambridge, United Kingdom.*

## **2011**

*ASCO-NCI-EORTC Molecular Targets and Cancer Therapeutics. Interrogating the heritable genome to achieve the goal of personalized cancer therapeutics. San Francisco, CA.*

*Alliance for Clinical Trials in Oncology - Group Meeting. GWAS in pancreatic cancer: leveraging discoveries from correlative science. Chicago, IL.*

*4<sup>th</sup> Golden Helix Pharmacogenomics Day. Pharmacogenomics in oncology and integrated discoveries. Cagliari, Italy.*

*University of Leiden. Opportunities for integrated discoveries in onco-pharmacology. Leiden, Netherlands.*

*Gentris Corporation. Opportunities for integrated discoveries in cancer pharmacology. Morrisville, NC.*

## **2010**

*1<sup>st</sup> Latin American Pharmacogenomics Congress. Genomic markers of survival in patients treated with cancer chemotherapy. San Juan, Puerto Rico.*

*National Cancer Institute - Centro di Riferimento Oncologico. Bioinformatics tools in pharmacogenomics. Aviano, Italy.*

## **2009**

*Golden Helix Symposium: Pharmacogenomics - paving the path to personalized medicine. Pharmacogenomics: an Odyssey. Athens, Greece.*

*Golden Helix Symposium: Pharmacogenomics - paving the path to personalized medicine. Early experience with genome-wide association studies in cancer chemotherapy. Athens, Greece.*

*2<sup>nd</sup> National Joined SIBioC-SIMeL Meeting. Can we personalize drug therapy in colorectal cancer patients? Naples, Italy.*

*From Pharmacogenetics to Personalised Cancer Therapy Meeting. Application of genome-wide technologies to identify novel candidate genes of treatment outcome. National Cancer Institute - Centro di Riferimento Oncologico. Aviano, Italy.*

*Indiana University. Pharmacogenomics of anti-angiogenesis therapy: from candidate genes to GWAS. Indianapolis, IN.*

*First Course on Pharmacogenetics in Medical Oncology. Hospital de la Santa Creu i Sant Pau. Recent advances on the role of heritable genetic variation of VEGF-pathway genes in cancer chemotherapy. Barcelona, Spain.*

## 2008

- 10<sup>th</sup> European International Society for the Study of Xenobiotics (ISSX) meeting.* Irinogenetics. Vienna, Austria.
- 15<sup>th</sup> North American Regional Meeting of the Society for the Study of Xenobiotics (ISSX).* The pharmacogenomics of anti-angiogenic therapy. San Diego, CA.
- Korean Cancer Association Annual Meeting.* Pharmacogenomics of anti-angiogenesis drugs. Seoul, South Korea.
- Korean Cancer Association Annual Meeting.* Genome-wide association studies of drug response in oncology. Seoul, South Korea.
- Meeting with the NIH Pharmacogenetics Research Network and the SNP Research center, Riken.* Preliminary analysis of CALGB 80303, a pancreatic cancer study. Tokyo, Japan.
- ASCO-NCI-EORTC Molecular Markers in Cancer Meeting.* Prospective germline pharmacogenetic testing for irinotecan and 5-fluorouracil. Hollywood, FL.
- CALGB Correlative Sciences and Pathology Educational Symposium: CALGB Fall Group Meeting.* A Genome-wide association study (GWAS) in CALGB 80303. Tampa, FL.
- National Cancer Institute - Centro di Riferimento Oncologico.* The phase I program at the University of Chicago. Aviano, Italy.
- US Food and Drug Administration, Office of Clinical Pharmacology.* The utility of pharmacogenomics in drug development and clinical practice in oncology. Silver Spring, MD.

## 2007

- Advances at the Forefront-Translational Medicine at the Bedside.* What an internist should know about pharmacogenomics. Napa, CA.
- 2<sup>nd</sup> Annual American Association for Cancer Research (AACR) International Conference on Molecular Diagnostics in Cancer Therapeutic Development: Maximizing Opportunities for Personalized Treatment.* Application of UGT1A1 genetic testing in patients treated with irinotecan. Atlanta, GA.
- 8<sup>th</sup> International Society for the Study of Xenobiotics (ISSX) meeting.* The application of pharmacogenomics in oncology. Sendai, Japan.
- 6<sup>th</sup> International Colorectal Cancer Congress.* Role of UGT1A1 as a determinant of irinotecan toxicity. Aventura, FL.
- 26<sup>th</sup> Annual Education Conference of the National Society of Genetic Counselors.* Pharmacogenomics in oncology. Kansas City, MO.
- 4<sup>th</sup> Workshop in a Series on Pharmacogenomics: Biomarkers and Pharmacogenomics in Drug Development and Regulatory Decision Making.* Understanding the role of gene variation in cancer chemotherapy. Bethesda, MD.
- National Cancer Institute - Centro di Riferimento Oncologico.* Cancer pharmacogenomics: candidate genes, pathway genes, and genome-wide analyses. Aviano, Italy.
- Hospital de la Santa Creu i Sant Pau.* Pharmacogenomic strategies in oncology. Barcelona, Spain.

## 2006

- Molecular Epidemiology Working Group of the American Association for Cancer Research.* Pharmacogenetics of irinotecan. Charleston, SC.

*International Symposium on Genetic Variation and Pharmacogenetics in Oncology*. The irinotecan case: possibilities and problems in improving cancer therapy by pharmacogenetics diagnostics. Göttingen, Germany.

*7<sup>th</sup> Annual Perspectives in Colorectal Cancer*. Tailored therapy through pharmacogenomics. Scottsdale, AZ.

*The Cancer Institute of Tuscany, Italy - Istituto Toscano Tumori*. Pharmacogenomics: can we individualize drug therapy? Florence, Italy.

*Merck and Co., Inc.* Cancer pharmacogenomics: clinical application and challenges. Rahway, NJ.

## 2005

*Cancer Education Consortium/AstraZeneca*. Molecular and Translational Workshop. Pharmacogenomics: overview. Amelia Island, FL.

*Drug development: Changing the Paradigm*. Pharmacogenomic biomarkers. Philadelphia, PA.

*Recent Advances in Pharmacogenomics, Korean Society of Applied Pharmacology*. Cancer pharmacogenomics. Seoul, South Korea.

*Asan Medical Center*. Pharmacogenomics: present and future. Seoul, South Korea.

*Medical Oncology Unit, Livorno Hospital*. Cancer pharmacogenomics 2005. Livorno, Italy.

## 2004

*Cancer Update 2004 Conference*. Application of genomics to anti-cancer drug therapies. San Antonio, TX.

*Pharmacogenetics Lectures 2004, Erasmus MC*. Pharmacogenetics in oncology. Rotterdam, Netherlands.

*Glucuronidation Workshop*. Role of UGT genetic variation in cancer chemotherapy. Dundee, Scotland.

*Beaumont DNA symposium*. Pharmacogenomics and clinical practice. Troy, MI.

*Clinical Trials and Drug Development of Anti-Cancer & Oncology Drugs*. Understanding the role of pharmacogenomics in monitoring responses for oncology clinical trials. Philadelphia, PA.

*The University of Texas MD Anderson Cancer Center Investigators' Workshop*. Irinotecan in colorectal cancer patients with UDP-glucuronosyltransferase 1A1 polymorphisms. San Diego, CA.

*Memorial Sloan-Kettering Cancer Center*. Pharmacogenetics in oncology: the example of "irinogenetics". New York, NY.

## 2003

*24<sup>th</sup> Winter Meeting of the EORTC-PAMM Group*. Pharmacogenomics of UDP-glucuronosyltransferases in cancer chemotherapy. Florence, Italy.

*2<sup>nd</sup> Annual Opinion Leader Summit: Targeted Therapies for the Treatment of Colorectal Cancer*. A phase I and pharmacogenetic trial of irinotecan in refractory cancer patients. Beaver Creek, CO.

*2<sup>nd</sup> Themes of the Clinical Pharmacology of Cochin: Updates on the clinical evaluation of the anticancer agents*. The relationship of genetic polymorphisms to toxicity and response of anticancer therapy. Hôpital Cochin, Paris, France.

## 2002

*National Cancer Center Hospital East and Yacult Central Institute for Microbiological Research.* Pharmacogenetics of glucuronidation in cancer chemotherapy. Tokyo, Japan.

*5<sup>th</sup> Annual Land O'Lakes Conference on Drug Metabolism/Applied Pharmacokinetics.* Pharmacogenomics and drug metabolism. Merrimac, WI.

*3<sup>rd</sup> International Cancer Congress New Trends in Cancer Therapy.* Pharmacogenetic studies on irinotecan, flavopiridol and epirubicin. Rovigo, Italy.

## Scientific Organizer - Scientific Committee Member (Meetings/Symposia/Conferences)

*2020 Golden Helix Summer School: Genomics into Medicine: How YOU do it.* 2020, Syros Island, Greece.

*2018 Golden Helix Summer School: Rare genomics: genomics of rare diseases, rare cancer, and rare drug outcomes.* 2018, Syros Island, Greece.

*Second Personalized Medicine Day Vienna: Making personalized medicine available to every citizen.* 2017, Vienna, Austria.

*Eleventh Annual Chapel Hill Pharmaceutical Sciences Conference.* 2017, Chapel Hill, NC, USA.

*2016 Golden Helix Summer School: Cancer genomics and individualized therapy.* 2016, Syros Island, Greece.

*5th Pan Arab Human Genetics Conference in conjunction with the 2013 Golden Helix Symposium: Helix into Health. Our Genome and Clinical Molecular Medicine.* 2013, Dubai, United Arab Emirates.

*Golden Helix Symposium: Genomic medicine: translating genes into health.* 2012, Turin, Italy.

*Golden Helix Symposium: Genetic analysis in translational medicine.* 2010, Athens, Greece.

*Golden Helix Symposium: Pharmacogenomics - paving the path to personalized medicine.* 2009, Athens, Greece.

## University of North Carolina (Lectures/Oral Presentations)

*UNC Healthcare, North Carolina Heart and Vascular, 10th Cardiovascular Symposium.* Precision medicine through genomics: current status and future developments. 2015.

*Gastrointestinal Oncology Clinical/Translational Research Seminar, Hematology/Oncology Section, Department of Medicine.* Vitamin D, vitamin D receptor, and the cure of cancer. 2015.

*Lineberger Comprehensive Cancer Center, Triade Golfers Against Cancer.* A clinical trial to personalize dosing of chemotherapy in metastatic colorectal cancer patients, 2013.

*Lineberger Comprehensive Cancer Center Retreat.* Pharmacogenetics of VEGF-pathway inhibitors, 2013.

*Cancer Genetics Faculty Lecture Series, Lineberger Comprehensive Cancer Center.* Opportunities and challenges in cancer personalized drug therapy, 2012.

*Department of Computer Science, CompGen Meeting.* Using the liver eQTL map as a platform for pharmacogenetic discoveries, 2011.

*Hematology and Oncology Division, School of Medicine. Testing hypotheses from the experience of phase I pharmacology studies, 2011.*

*University of North Carolina at Chapel Hill. Using genetic and genomic approaches to improve anti-cancer therapy, 2010.*

### **University of Chicago (Lectures/Oral Presentations)**

*Institute for Translational Medicine's Biological Translational Research Workshop series. "All K All the Time" program. Genome-wide molecular epidemiology of treatment outcome and cancer risk, 2010.*

*Department of Human Genetics. Cancer Genetics Review. Cancer pharmacogenomics, 2006.*

*Department of Medicine Grand Rounds. Pharmacogenomics: can we individualize drug therapy?, 2006.*

*Recent Advances in Thoracic Oncology. VEGF pharmacogenomics, 2005.*

*Recent Advances in Thoracic Oncology. Irinotecan pharmacogenetics, 2004.*

*Committee on Clinical Pharmacology and Pharmacogenomics. Principles of pharmacogenetics, 2004.*

*Section of Hematology/Oncology, Monday Conference. "...good drugs and deadly drugs...", 2004.*

*University of Chicago Cancer Research Center Friday's Seminars. Complementary and alternative medicine (CAM) and irinotecan metabolism, 2003.*

### **Other Activities at the University of Chicago**

Judge at the Annual Senior Scientific Session (2006 - 2008).